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ABSTRACT 
Resistin and visfatin are secreted by adipose tissue and are potential regulators of 
inflammation and insulin sensitivity. This study examined the effects of exercise and 
diet-induced weight loss on resistin and visfatin. Twenty six sedentary obese women 
were randomly assigned into control group (C) or an exercise plus diet group (DE) that 
involved circuit resistance-exercise (4 d/week) with walking (10,000 steps/d, 3 d/week) 
while consuming 1,200 kcal/day for 1 week and 1,500 kcal/d diet for 11 weeks 
consisting of 45:30 % Protein:Carbohydrate. Body composition and fasting blood 
samples were obtained and analyzed by MANOVA and Pearson correlation analysis. 
Data are presented as mean±SD changes from baseline. Participants in the DE group lost 
more weight (DE: -5.9±4.0; C: 0.64±1.4 kg, p<0.001) and fat (DE: -5.1±4.5; C: 0.4±1.5 
kg, p=0.001). Significant differences were seen between groups in leptin (DE: -
17.8±21.9; C: 4.5±16.0 ng/ml, p=0.003), IL-6 (DE: -1.9±4.2; C: 2.7±1.2 ng/ml, p=0.001) 
and TNF-α (DE: -.2±2.1; C: 1.7±1.5 ng/ml, p=0.013)  while visfatin (DE: 0.85±14.9; C: 
20.2±37.1 ng/ml, p=0.10) and insulin (DE: -8.5±15.0; C: 0.12±7.7 IU/ml, p=0.07) 
tended to differ between groups. No significant differences were seen in changes in 
resistin (DE: 18.6±100; C: 59.9±162.2 ng/ml, p=0.452) or glucose (DE: -3.8±19.8; C:-
2.8±6.9 %, p=0.87). Significant correlations were seen between changes in IL-6 and 
resistin (r=0.430, p=0.028) and changes in resistin and visfatin (r=0.417, p=0.034). 
These findings indicate that exercise and diet-induced weight loss have an effect on 
resistin and visfatin. 
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IL-8  Interleukin-8 
IL-10  Interleukin-10 
TNF-α  Tumor Necrosis Factor- Alpha 
MCP-1 Monocyte Chemoattractant Protein-1 
IRS-1  Insulin Receptor Substrate-1 
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MAPK  Mitogen Activated Protein Kinase 
HOMA Homeostasis Model Assessment 
HOMA-IR Homeostasis Model Assessment of Insulin Resistance 
HDL  High Density Lipoprotein 
BMI  Body Mass Index 
ESNL  Exercise and Sport Nutrition Laboratory 
CVD  Cardiovascular Disease 
TGF-𝛽𝛽  Tumor Growth Factor-Beta 
IL-1Ra  Interleukin-1 receptor antagonist 
NF𝜅𝜅B  nuclear factor kappa-light-chain-enhancer of activated B cells 
IL-1 𝛽𝛽  Interleukin-1 Beta 
NEFA  Non-esterified Fatty Acid 
PPAR  Peroxisome proliferator-activated receptor 
PAI-1  Plasminogen activator inhibitor-1 
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ICAM1 Intercellular Adhesion Molecule 1 
TNF-R type 2 Tumor necrosis factor receptor 2 
LPS  Lipopolyssacharide 
Retn  Resistin 
CAD  Coronary Artery Disease 
NAD  Nicotinamide adenine dinucleotide 
WAT  White Adipose Tissue 
CD14+ Cluster of Differentiation 14 
MEK1  Mitogen-activated Protein Kinase Kinase 1 
Nampt  Nicotinamide Phosphoribosyltransferase 
PBEF  Pre-B cell colony-enhancing factor 
GH  Growth Factor 
HDLc  High Density Lipoprotein Cholesterol 
sTNFR1 Soluble Tumor Necrosis Factor Receptors 1 
SDS-BMI Standard Deviation Score -Body Mass Index (BMI) 
A1C  Glycated Hemoglobin 
HsCRP High-sensitivity C-reactive protein 
VO2max  Maximum Rate of Oxygen Consumption 
NO  Nitric Oxide 
HMB  β-Hydroxy β-Methylbutyrate 
DHEA  Dehydroepiandrosteron 
DEXA  Dual Energy X-ray Absorptiometry 
EDTA  Ethylenediaminetetraacetic acid 
ELISA  Enzyme-linked Immunosorbent Assay 
SA-HRP Streptavidin-horseradish peroxidase 
FFM  Fat Free Mass 
VAT  Visceral Adipose Tissue 
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CHAPTER I 
INTRODUCTION 
Obesity has become a public health crisis in United States. Nearly two thirds of 
adult Americans are either overweight or obese [1, 2]. Despite the emphasis on the 
benefit of healthier diets and increased physical activity by health professional, media, 
public and mass educational campaigns, the prevalence of obesity in United States has 
more than doubled over the past four decades. There exist large disparities between 
population groups and trends in the associated patterns [1-3]. In 2009-2010, the 
prevalence of obesity was 35.5% among adult men and 35.8% among adult women [4]. 
There are two major factors that contributed to the increase in obesity prevalence, 
plentiful supplies of inexpensive foods and sedentary jobs [5]. Obesity has many health, 
social, psychological, and economic consequences for  both the individual being affected 
and the society [6]. According to one study, medical expenditures attributed to 
overweight and obesity in 2008 was $209.7 billion [7].  
Obesity is associated with atherosclerotic cardiovascular disease (ASCVD) and 
can also be an underlying risk factor for cardiovascular diseases [8]. Obesity is also 
accompanied by other medical complications such as diabetes, fatty liver, cholesterol 
gallstones, sleep apnea, osteoarthritis, and polycystic ovary disease. These disorders are 
commonly found in individuals who have metabolic syndrome [9]. Metabolic syndrome 
is the collection of risk factors those of which contribute to ASCVD. It includes major 
risk factors (hypercholesterolemia, hypertension, and hyperglycemia) and emerging risk 
factors (atherogenic dyslipidemia, insulin resistance, proinflammatory state, 
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prothrombotic state). Obesity is associated with a chronic inflammatory response, 
characterized by abnormal adipokine production, and the activation of some pro-
inflammatory signaling pathways, resulting in the alteration of several biological 
markers of inflammation such as C-reactive protein (CRP), IL-6, TNFα, adiponectin, 
leptin, resistin, visfatin etc. [10-14]. Conversely, a reduction in body weight is 
accompanied by a decrease or even a normalization of these biological parameters [15-
21]. The exact mechanism of inflammation is unclear but several inflammatory factors 
have been proposed as stimulators such as infectious agent leading to endothelial injury 
[22]. Both central adiposity and obesity have also been associated with abnormal lipid 
and lipoprotein levels [23, 24].  
Exercise and diet play an important role in weight loss in overweight and obese 
people. Many research studies have shown that diet and exercise are highly effective in 
increasing weight loss that leads to improve inflammatory markers of obesity and 
enhance health and overall fitness [25-28]. Most research have shown that programs 
including both diet and exercise produce greater weight loss than diet alone in 
overweight and obese individuals soon after intervention period and after 1 year of 
follow up [29-31]. Exercise and diet-induced weight loss have the ability to improve 
overall body health by reducing total body weight and can have a positive effect on body 
composition [32, 33]. Nevertheless, the main pathogenic mechanisms of obesity still 
remain unclear and more research needs to be done. 
Several inflammatory markers related to obesity have been studied in the last few 
years. Among them, two recently discovered inflammatory markers, resistin and visfatin 
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have gained more attention due to their contradictory behavior and potentially 
contributing factors to insulin resistant which leads to diabetes. In 2001, resistin (or 
‘resistance to insulin’) was originally discovered in mice. It was named due to its ability 
to resist (interfere with) insulin action [34]; which was initially proposed as a link 
between obesity and diabetes. Several studies have reported positive correlations 
between resistin levels and insulin resistance in vivo and in vitro [34]. Recently, resistin 
has been associated with metabolic syndrome components and on the other hand, it has 
been linked with early atherosclerosis in obese children [35]. Finally, resistin has been 
demonstrated to stimulate the secretion of several inflammatory factors like TNF-𝛼𝛼, IL-
6, IL-8, and MCP-1, known to play a role in the mechanism of insulin resistance [36]. 
Therefore, resistin may have an indirect effect on insulin resistance in humans through 
exacerbating inflammation, which has been shown to disturb insulin sensitivity. 
Fukuhara et al. [37] recently identified a new adipokine mainly synthesized and 
secreted in visceral fat called ‘visfatin’. Plasma visfatin levels were strongly correlated 
with total fat mass but not so much with subcutaneous fat mass. However, these results 
remain controversial [38-41]. According to both genetic and nutritional obesity models, 
visfatin expression is induced only in visceral adipose tissue. In vitro, just like insulin, 
visfatin enhances glucose uptake by myocyte and adipocyte and inhibits hepatocyte 
glucose release [37] . Visfatin and insulin have the same affinity for the insulin receptor, 
with visfatin physically interacting with the receptor, but at a different site. Its insulin-
like effects are also observed in the insulin-transduction pathway. Just like insulin, 
visfatin induces tyrosine phosphorylation of insulin receptors IRS-1 and -2, and 
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activation of phosphatidylinositol-3-kinase, protein kinase B and MAP kinase. 
Regardless of these similarities between visfatin and insulin, there are also marked 
differences between the two [37]. The most important difference is that visfatin levels do 
not significantly change in fed or fasting states. The plasma levels of visfatin are 10% 
lower in a fasting state and 3% in a fed state when compared to insulin levels. These 
differences in plasma concentrations could account for the mild effect of visfatin in 
glycaemia. However, it is too early to consider this adipokine in the development of 
hypoglycemic drugs, recent research has shown that serum visfatin increases with 
progressive beta-cell deterioration in type 2 diabetic patients [42] . The above mentioned 
studies strongly suggest that visfatin could be primarily regarded as an inflammatory 
mediator involved in several pathological processes.  
Additional research is warranted to understand the effects of exercise and diet-
induced weight loss on resistin and visfatin. Moreover, ways in which exercise and diet-
induced changes in resistin and visfatin may affect secondary responses such as insulin 
sensitivity, insulin resistant and their link to diabetes, triglycerides, HOMA, HDL etc. 
Thus, the main foci of this study were to examine whether obesity is associated with 
increase in inflammation; whether exercise and diet-induced weight loss reduces 
inflammatory markers- resistin and visfatin; how these inflammatory markers correlate 
with each other; how resistin and visfatin correlate with anthropometric indices and 
other inflammatory markers such as IL-6, TNF-α, and, whether changes in levels of 
markers explain how exercise and diet-induced weight loss can be beneficial in 
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improving markers of health, fitness and inflammation that may potentially lead to 
understanding the mechanism of certain diseases or disorders.   
Statement of problem 
 
Does exercise and diet-induced weight loss affect the inflammatory markers such 
as resistin and visfatin associated with obesity and how these markers correlated with 
anthropometric indices, blood markers and other inflammatory markers such as IL-6 and 
TNF-α? 
Purpose of the study 
 
The purpose of the study was to examine how exercise and diet-induced weight 
loss affect the markers of inflammation, resistin and visfatin and how these markers 
correlate with anthropometric indices, blood cholesterol indices and other inflammatory 
markers. 
General study design 
 
This study was conducted as a randomized, repeated measure, prospective 
clinical trial in an obese female population ages 18-65 years. Participants meeting 
eligibility criteria were randomly assigned to a 12-week exercise and diet-induced 
weight loss group designed to improve fitness and promote fat loss and reduce 
inflammatory markers or a non-diet, non-exercise control group. The independent 
variables were exercise and diet intervention. The dependent variables were body 
composition (weight, fat mass, fat free mass, percent body fat); markers of fitness; 
inflammatory markers such as resistin, visfatin, IL-6, TNF-α, insulin, leptin, HDL, 
triglyceride and HOMA.  
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Hypotheses 
 
H1-The exercise and diet intervention will promote significantly greater weight 
loss and changes in body composition compared to controls.  
H2-The exercise and diet intervention will promote significant decrease in resistin 
levels compared to the controls  
H3-The exercise and diet intervention will promote significant decrease in visfatin 
levels compared to the control 
H4-There will be significant correlation between changes in resistin and changes 
in visfatin between the groups across the intervention period 
H5- There will be significant correlation between changes in resistin and changes 
in leptin between the groups across the intervention period 
H6- There will be significant correlation between changes in visfatin and changes 
in leptin between the groups across the intervention period 
H7- There will be significant correlation between changes in resistin and changes 
in TNF-α between the groups across the intervention period 
H8- There will be significant correlation between changes in visfatin and changes 
in TNF-α between the groups across the intervention period 
H9- There will be significant correlation between changes in visfatin and changes 
in triglyceride level between the groups across the intervention period 
H10- There will be significant correlation between changes in visfatin and changes 
in waist-to-hip ratio level between the groups across the intervention period 
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H11- There will be significant correlation between changes in resistin and changes 
in waist-to-hip ratio level between the groups across the intervention period 
H12- There will be significant correlation between changes in resistin and changes 
in triglyceride level between the groups across the intervention period 
H13- There will be significant correlation between changes in resistin and changes 
in REE between the groups across the intervention period 
H14- There will be significant correlation between changes in visfatin and changes 
in REE between the groups across the intervention period 
H15- There will be significant correlation between changes in resistin and changes 
in IL-6 between the groups across the intervention period 
H16- There will be significant correlation between changes in visfatin and changes 
in IL-6 between the groups across the intervention period 
Delimitations 
 
The research study followed the guidelines listed below:  
1. There were approximately 50 sedentary overweight female participants (BMI > 
27) ages 18-65 who participated in the study.  
2. Participants were recruited with flyers posted on campus, physician 
offices/clinics, and retirement facilities. Advertisements were run in the local newspapers 
and radio.  
3. Familiarizations and testing sessions were conducted in the Exercise and Sport 
Nutrition Laboratory (ESNL) at Texas A&M University.  
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4. Participants were randomly assigned to one of two treatment groups, (exercise 
and diet-induced weight loss group and a control group). 
5. Participants followed the exercise prescription guidelines in a supervised 
exercise program three times per week throughout the investigation. 
Limitations 
 
Participants who were sedentary and obese females (BMI > 27) between the ages 
of 18-65 years, had to meet medical clearance and qualifying criteria. Participants in the 
exercise and diet-induced weight loss group were required to adhere to an exercise 
program three times per week throughout the investigation. 
Assumptions 
 
Participants followed the exercise and diet-induced weight loss program as 
specified by the assigned high protein diet regimen only. Participants followed verbal and 
written instructions, on more than one occasion to refrain from exercise for 48 hours prior 
to baseline testing. Participants fasted for 12 hours prior to lab collection. Participants 
followed the intensity guidelines for all work outs as the instructions. 
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CHAPTER II 
 
LITERATURE REVIEW 
Background  
 
Obesity is a major public health concern worldwide, and is one of the most 
prevalent non-communicable diseases [43]. Obesity can be measured in different ways. 
The assessment methods measures different aspects of obesity such as the total or 
regional obesity.  Each method’s appropriateness and scientific acceptability depends on 
the situation since each method has its own advantages and disadvantages. Each method 
also produces different results when it is used to estimate morbidity and mortality. When 
there is increased body fat, there will also be necessary increases in some lean tissue 
including the fibrous and vascular tissues in adipose tissue, heart muscle, bone mass, and 
truncal or postural musculature. All these non-fat tissues have a higher density (1.0 g/ml) 
than fat (0.7 g/ml). The density of non-fat tissues is also increased by physical activity, 
which of course tends to reduce body fat. While body mass index (BMI) has traditionally 
been used to identify overweight and obese individuals, waist circumference was 
developed initially as a simpler and potentially a better indicator of health risk than BMI 
in health promotion. Waist circumference is the best anthropometric predictor of visceral 
fat and at least as good an indicator of total body fat as BMI or skinfold thicknesses [44]. 
Waist circumference alone is also a better predictor of visceral and total fat as compared 
to waist to hip ratio. Waist circumference is minimally related to height, so correction 
for height (as in waist to height ratio) does not improve its relation with intra-abdominal 
fat or ill health. People with a large waist are many times more at risk of ill health, 
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including features of metabolic syndrome (such as diabetes, hypertension, and 
dyslipidemia) as well as shortness of breath and poor quality of life. These increased 
risks also apply to people whose BMI is normal but who have a large waist. However, 
BMI and waist circumference are collinear, so combining the two measures adds 
relatively little to no risk prediction. Waist to hip ratio was introduced—mainly as a 
result of Swedish research—on the assumption that it would predict fat distribution 
better than waist circumference alone. Subsequent research, however, showed that it did 
not. Hip circumference does have a relation to health and disease, but in an inverse way, 
such that a relatively large hip circumference is associated with lower risks of diabetes 
and coronary heart disease. This is probably because hip circumference reflects muscle 
mass, which is reduced in type 2 diabetes and inactivity [44].  
Obesity has inflammatory component which is in relationship with alterations 
such as insulin resistance, atherosclerosis, hypertension, and some types of cancer [45, 
46]. Overweight and obese individuals have altered circulatory levels of inflammatory 
cytokines, such as TNFα, IL-6, C-reactive protein (CRP), IL-18, Resistin and Visfatin 
[47-50]. Measures of body fat have stronger correlation with inflammatory markers than 
BMI or total body fat [48, 50].  
The application of lifestyle interventions, such as caloric restriction and exercise 
training, has been strongly advocated for the treatment of obesity and its related 
metabolic dysfunctions. Caloric restriction is a reasonable treatment for inflammation in 
obesity [51, 52]. However, dietary weight loss can become less effective as a long-term 
anti-inflammatory intervention [53]. Regular exercise can potentially modify metabolic 
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hormones [54] and may be important for the treatment of chronic inflammation and 
obesity-related conditions like the metabolic syndrome. 
Brown and white adipose tissue 
 
Both brown fat cells and muscle cells derived from the same stem cells in the 
embryo, having the same marker. The function of brown fat is to generate heat by 
burning calories. Brown fat is more commonly found in hibernating animals and 
newborns. The quantity of brown fat significantly decreases after life as an infant. Adults 
who have comparatively more brown fat tend to be younger and slender and have 
normal blood sugar levels. We can generate more brown fat by exercising, which can 
convert white-yellow fat to a more metabolically active brown fat; getting enough high-
quality sleep, as proper melatonin production influences the production of brown fat; and 
exposing yourself to the cold regularly, such as exercising outdoors in the wintertime or 
in a cold room [55].  
White fat is composed of a single lipid droplet and has far less mitochondria and 
blood vessels, thus resulting in its lighter white or yellow appearance. White fat is the 
predominant form of fat in the body, originating from connective tissue. It has many 
functions like providing largest energy reserve in the body, thermal insulator and 
cushion for our internal organs and protective cushions for our internal organs and 
during external interactions with our environment. It is a major endocrine organ, 
producing one form of estrogen as well as leptin, a hormone that helps regulate appetite 
and hunger. It’s also got receptors for insulin, growth hormone, adrenaline, and cortisol 
(stress hormone). Abdominal obesity (visceral fat) is associated with metabolic 
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syndrome—a group of symptoms that signal an increased risk for heart disease, diabetes, 
and cancer. Excess white fat throughout the body is associated with an increased risk of 
breast, colon, esophageal, gall bladder, and pancreatic cancer. It’s also associated with 
sleep apnea, and physical disabilities such as knee arthritis. White adipose tissue is no 
longer considered an inert tissue mainly devoted to energy storage but is emerging as an 
active participant in regulating physiologic and pathologic processes, including 
immunity and inflammation. Macrophages are components of adipose tissue and actively 
participate in its activities [56]. Furthermore, cross-talk between lymphocytes and 
adipocytes can lead to immune regulation. Adipose tissue produces and releases a 
variety of proinflammatory and anti-inflammatory factors, including the adipokines 
leptin, adiponectin, resistin, and visfatin, as well as cytokines and chemokines, such as 
TNF-α, IL-6, monocyte chemoattractant protein 1, and others [57, 58]. Proinflammatory 
molecules produced by adipose tissue have been implicated as active participants in the 
development of insulin resistance and the increased risk of cardiovascular disease 
associated with obesity [59]. In contrast, reduced leptin levels might predispose to 
increased susceptibility to infection caused by reduced T-cell responses in malnourished 
individuals [60]. Altered adipokine levels have been observed in a variety of 
inflammatory conditions, although their pathogenic role has not been completely 
clarified. 
Obesity: an immune disease?  
 
Obesity, state of malnutrition by excess, leads to defective immune function. 
Excess body fat is associated with changes in leukocyte count such as neutrophils, 
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monocyte and lymphocyte counts but lower T- and B-cell mitogen-induced 
proliferation [61]. Could altered immune system underlie the onset of obesity? This 
conclusion would be too speculative or not sufficiently founded at the moment, but we 
can say, at least immune dysfunction is a major contributor to obesity associated 
alterations like inflammation and insulin resistance. Macrophages aggregates grew 
larger with increasing degree of obesity, similar to those observed in other 
inflammatory conditions, led to the idea that macrophages aggregate could partially 
explain the obesity-related inflammatory state [56]. There are two types of phenotypic 
macrophages described that have been related to the obesity: one known as M1 
(classically activated) acts as pro-inflammatory and another is M2 (alternatively 
activated) acts as anti-inflammatory. In obesity, there is a switch from M2 to M1 
phenotype which is pro-inflammatory [62]. Furthermore, most of the research findings 
showed absence of M2 phenotype associated with a higher susceptibility to obesity, 
inflammation and insulin resistance [63].  
Prevalence of obesity 
 
The prevalence of obesity in United States has more than doubled over the past 
four decades although there are large disparities between population groups and 
continuing changes in the associated patterns [1-3]. The prevalence of obesity for adults 
ages 20 to 74 years increased by 7.9 percentage points for men and by 8.9 percentage 
points for women between 1976-1980 and 1988-1994, and subsequently by 7.1 
percentage points for men and by 8.1 percentage points for women between 1988-1994 
and 1999-2000 [64]. In 2007-2008, the prevalence of obesity was 32.2% among adult 
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men and 35.5% among adult women [65] which became 35.5% in men and 35.8% in 
women respectively in 2009-2010 [4]. Women have experienced a particularly sharp 
increase in the prevalence of obesity from 40.2% to 63.9% in the last few years. 
According to the recent published data, 39.96% (weighted n = 36325297) of men and 
29.74% (weighted n = 28894630) of women were overweight and 35.04% (weighted 
n=31847198) of men and 36.84% (weighted n = 35792733) of women were obese. The 
weight status distribution was similar for both sexes across racial groups, except for non-
Hispanic white women, who had higher normal weight than the overweight category. 
Over 20 years, the greatest increase in the proportion of patients in the obesity class 3 
category was among non-Hispanic black women [66]. 
Inflammation and its markers 
 
Inflammation is a protective response to extreme challenges to homeostasis, such 
as infection, tissue stress, and injury. Inflammatory signals including cytokines, 
chemokines, biogenic amines, and eicosanoids participate in different biological 
processes ranging from local vascular responses to alterations of body temperature. 
Regardless of this complexity and diversity of functions, all the activities of 
inflammatory signals can be described in terms of their effects as a part of homeostasis. 
Inflammatory signals can directly stimulate or inhibit the flows of various homeostatic 
systems such as TNF-α and IL-1b activate lipolysis, inhibit gluconeogenesis, and 
increase vascular permeability to fluids and solutes, while IL-6 changes hepatic protein 
synthesis [67]. Inflammation increases the production of procoagulant factors, down-
regulates anticoagulant mechanisms, and promotes tissue factor (TF) expression on 
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white blood cells and endothelial cells [68]. Cytokines, chemokines and adhesion 
molecules facilitate inflammation [69]. Endothelial cells also secrete growth factors and 
chemokines such as interleukin (IL)-6, IL-8, and IL-10 [70]. The process of thrombus 
resolution and inflammation culminates in vein wall thickening and fibrosis 
[71].Overall, inflammation is a very important process within homeostatic circuit and its 
markers could provide more detailed insight about the mechanism or pathophysiology of 
various diseases or disorders.  
Obesity and inflammatory markers 
 
 The obesity associated state of chronic low-grade systemic inflammation, termed 
“metabolic inflammation”, is considered a focal point in the pathogenesis of multiple 
disorders/diseases like insulin resistance, atherosclerotic and coronary diseases etc. [46, 
72, 73]. Adipose tissue is a complex and active secretory organ that both sends and 
receives signals modulating energy expenditure, appetite, insulin sensitivity, endocrine 
and reproductive functions, bone metabolism, inflammation, and immunity. It also acts 
as a reservoir to store excess nutrients as triacylglycerol [12] and to release free fatty 
acids during fasting. Visceral adiposity, rather than simply a high body mass index 
(BMI), correlates well with increased risk of CVD and diabetes. However, the 
biochemical and physiologic reasons for this are still unclear. One possible explanation 
is that visceral fat has direct access to the portal circulation as compared to subcutaneous 
white adipose tissue that leads to the substances produced by visceral fat directly 
affecting the liver.  
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Adipocytes synthesize and secrete the proinflammatory cytokines like tumor 
necrosis factor alpha (TNF-𝛼𝛼) and the hormone leptin which regulates appetite and 
energy balance [74]. Evidence shows that the adipose tissue secretes more than 50 
hormones and signaling molecules, collectively called adipokines. These adipokines play 
a role in an autocrine, paracrine, or systemic manner and influence several physiological 
processes concerning energy, glucose metabolism, and immunity [75]. Adipose tissue 
from lean individuals preferentially secretes anti-inflammatory adipokines such as 
adiponectin, transforming growth factor beta (TGF𝛽𝛽), interleukin (IL)-10, IL-4, IL-13, 
IL-1 receptor antagonist (IL-1Ra), and apelin. In contrast, obese adipose tissue mainly 
releases proinflammatory cytokines among which are TNF-𝛼𝛼, IL-6, leptin, visfatin, 
resistin, angiotensin II, and plasminogen activator inhibitor 1 [73]. We still don’t know 
the role of increased cytokine production in obesity. We can only speculate that the 
answer can be searched in the enlarged, lipid loaded adipocytes. There must be 
mechanisms operating within and from the adipose cell in order to maintain or restore 
energy homeostasis in a situation of excessive nutrient inflow and storage. There should 
be a regulatory mechanism constituted by local production of these cytokines to stop the 
hypertrophied adipocyte from storing lipids. The problem arises when this becomes a 
systemic chronic state from a local reaction when the inflammatory response cannot be 
resolved due to sustained obesity. The mechanism between obesity and chronic low 
grade inflammation are yet not entirely understood, but different likely explanations 
have been proposed.   
 17 
 
TNF-𝛼𝛼 is a potent proinflammatory cytokine, primarily secreted from myeloid 
cells via activation of MAPK and NF𝜅𝜅B signaling pathways, resulting in the release of 
other inflammatory cytokines, such as IL-1𝛽𝛽 and IL-6 [76]. Leptin was one of the first 
proteins shown to be secreted from adipose tissue [74]. Leptin is primarily secreted by 
adipocytes proportionally to fat cell mass and is well known for its key contribution to 
energy metabolism [77]. Leptin exerts its effect on energy balance mainly by acting on 
the brain, either directly or indirectly by activating specific centers in the hypothalamus 
to decrease food intake, to increase energy expenditure, to influence glucose and lipid 
metabolism, or to alter neuroendocrine function. However, leptin levels are increased in 
obese subjects, with little or no impact to regulate energy homeostasis, which coined the 
well-established phrase “leptin resistance” in obesity. Certainly, preclinical and clinical 
experiments showed that obese rodents and humans displayed leptin resistance that may 
directly contribute to the reduction of lipid oxidation in insulin-sensitive organs, leading 
to accumulation of lipids and insulin resistance [78, 79]. The role of leptin on insulin 
resistance is still not fully understood. Leptin is decreased in low insulin states, such as 
experimentally induced diabetes, and increases after insulin treatment [80]. In humans, 
insulin resistance is associated with elevated plasma leptin levels independently of body 
fat mass [81]. However, in patients with lipodystrophy, a condition characterized by 
almost complete lack of adipose tissue [82], leptin levels are very low and correlate 
significantly with markers of insulin resistance [83]. Leptin therapy in lipodystrophic 
patients improves their metabolic state with remarkable improvements in insulin 
sensitivity, suggesting that leptin acts as a signal that contributes to regulation of total 
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body sensitivity to insulin [84]. Unlike leptin, the circulating levels of adiponectin, a 
hormone produced predominantly by adipocytes, are decreased in obesity [85]. 
Adiponectin has important insulin sensitizing effect: adiponectin-deficient transgenic 
mouse showed improved insulin sensitivity [86] and association studies have 
consistently linked plasma adiponectin levels to insulin sensitivity in rodent models and 
in humans [87].  
Adipokines enlisted in regulation of insulin resistance are adiponectin, leptin, 
resistin, visfatin, chemerin, TNF-𝛼𝛼, IL-1, IL-6, IL-8, IL-10, plasminogen activator 
inhibitor 1, monocyte chemoattractant protein-1, and retinol binding protein-4. 
Fatty acids can induce inflammation 
 
 Abnormally increased levels of blood lipid, including NEFA, are a common 
feature in obesity [88]. The chemical nature of fatty acids is relevant to triggering the 
inflammatory response. According to this hypothesis, the adipose tissue as a whole has 
limited capacity to expend and to store energy. Exceeding this limit leads to enhanced 
lipolysis within the adipocyte and the subsequent release of Non-esterified fatty acid 
(NEFA) into the blood stream. NEFA reach other tissues and organs, and exert toxic 
effects on them, e.g. resistance to insulin action; a phenomenon known as lipotoxicity. 
According to some studies on weight discordant twins, obese individuals showed signs 
of insulin resistance and stimulated inflammatory and immune response pathways in 
adipose tissue [89]. How can fatty acids elicit an inflammatory response? It has been 
suggested that fatty acids modulate adipokine production or secretion [90, 91]. 
Alternatively, NEFA may directly induce inflammatory pathways through activation of 
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cell receptors. For instance, they are natural ligands for the PPAR. These transcription 
factors regulate cell metabolism and adipocyte differentiation, and can also suppress the 
activity of the NF-kB, another transcription factor crucial in the initiation of the 
inflammatory response. In addition, PPAR seem to be involved in the aforementioned 
phenotypic switch of adipose tissue macrophages (from M2 or anti-inflammatory to M1 
or pro-inflammatory) [92]. 
Resistin and its association with obesity 
 
Steppan et al [93] described resistin as an antagonist to insulin in both in vitro 
and in vivo environments. They also showed that resistin has higher concentration in 
obese and diabetic mice. Exogenous administration of resistin increases plasma glucose 
levels and its endogenous production in rodents [34, 94]. Resistin  is produced in 
humans by mononuclear cells such as macrophages and by both adipocytes and 
macrophages in rodents [34, 95] while some other chemokines like TNF-α, IL-6, MCP-
1, visfatin, and PAI-1 are expressed in adipocytes as well as activated macrophages 
and/or other immune cells. The relative amounts of each produced by the adipocyte 
versus the macrophages present in the adipose tissue are still unclear. The potential role 
of resistin as mediator linking adipose tissue, inflammation, and immunity has been 
recently reviewed [95]. Resistin has also been shown as a pro-inflammatory 
adipocytokine which enhances during marathon race and associates with markers of 
cartilage degradation [96].  
It is suggested that resistin is engaged in inflammatory conditions in humans by 
means of its secretion in substantial quantities by mononuclear cells. Also, resistin levels 
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are mutually correlated with those of cell adhesion molecules such as ICAM1 in patients 
with obstructive sleep apnea, and in atherosclerotic patients, they are positively 
associated with other markers of inflammation, such as soluble TNF-R type II and 
lipoprotein-associated phospholipase A2 [97, 98]. Furthermore, LPS has been reported 
to induce resistin gene expression in primary human and murine macrophages via a 
cascade involving the secretion of pro-inflammatory cytokines, and in human peripheral 
blood mononuclear cells, resistin seems to induce and be induced by IL-6 and TNF 
(induction of these cytokines by resistin occurring via the NFκB pathway) [36, 99]. 
Human and rodent resistin gene and protein sequences share about 60% identity, 
less than most hormones conserved across species [100], yet, the genes are located on 
the same chromosome, and with the gene encoding resistin (Retn) on mouse 
chromosome 8 being located a similar distance from the insulin receptor gene as is the 
Retn gene on human chromosome 19. In addition, as in rodents, resistin levels decrease 
with thiazolidinedione (anti-diabetic) treatment in humans [101]. The lack of human 
resistin expression in adipocytes appears to be attributable to loss of a genomic binding 
site for the nuclear receptor peroxisome proliferator-activated receptor g (PPARg), 
which controls the adipocyte-specific expression of the mouse Retn gene [102]. The 
expression and secretion of resistin by human mononuclear cells are dramatically 
induced by inflammatory stimuli, [103-105], which also increase circulating resistin 
levels [98, 99]. Inflammation is increasingly recognized to play a pathogenic role in 
obesity and type 2 diabetes, as well as cardiovascular disease [46, 106]. As discussed 
below, recent genetic and epidemiologic data connect resistin to these human diseases.  
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Recently, in a study conducted by Silha et al on plasma resistin, adiponectin and 
leptin levels in lean and obese subjects. There was 17 lean subjects with a mean body 
mass index (BMI) of 23 and 34 non-diabetic obese individuals with a mean BMI of 
nearly 33. Insulin resistance was assessed using the homeostasis model assessment ratio 
(HOMA-Insulin Resistance) formula derived from fasting insulin and glucose levels. 
Results showed that resistin levels were not significantly different between the two 
groups but were significantly higher in women compared with men, 35.4±6.5 (S.E.) vs 
15.4±2.9 mg/l, P <0.01. Resistin did not correlate with BMI but did significantly 
correlate with HOMA-Insulin Resistance, P<0.01, and this correlation remained 
significant after adjustment for gender and BMI. Leptin levels were significantly higher 
in obese subjects and women and correlated with HOMA-Insulin Resistance and resistin, 
whereas there was no significant correlation between adiponectin and either leptin or 
resistin.   
Epidemiologic evidence for resistin in human insulin resistance and diabetes 
 
A mouse model in which human resistin is expressed primarily by monocytes 
and macrophages, as is the case in humans, is predisposed to developing insulin 
resistance, suggesting that the metabolic effects of resistin might be translatable from 
rodents to humans [107]. Given the association of resistin and insulin resistance in 
rodents, many studies have investigated the correlation between circulating resistin 
levels and type-2 diabetes. The results of initial efforts were conflicting, with some, but 
not all, studies identifying a significant correlation between serum resistin level and 
insulin resistance or type 2 diabetes [101].  
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Higher levels of resistin were observed in subjects with diabetes versus controls 
[108]. At least some of the association between resistin and insulin resistance in humans 
seems attributable to other factors known to affect insulin sensitivity, such as obesity and 
inflammation. However, although most studies have analyzed whether the relative risk 
associated with increased resistin levels is independent of previously established risk 
factors, the converse analysis has rarely been performed, leaving open the possibility 
that the biological effect of these other risk factors is mediated by resistin. Whether 
resistin is an active player or merely a responder in metabolic dysfunction cannot be 
fully determined without an understanding of the regulation of resistin itself. Genetic 
determinants of resistin expression might provide additional clues about the role of 
resistin in human susceptibility to disease. 
Evidence for resistin in human atherosclerosis and coronary artery disease 
 
Elevated resistin predicted the presence and severity of CAD, correlating with 
coronary artery calcium score in asymptomatic healthy subjects [98], and in patients 
undergoing angiography for chest pain [109, 110]. A European case–control study of 
26,490 healthy individuals found a relative risk of 2.09 for the development of 
myocardial infarction in those in the highest quartile of resistin, adjusted for CRP [111]. 
Moreover, a Chinese study of 225 cases and controls revealed a markedly increased risk 
of CAD (OR = 3.01) in individuals with the G/G genotype, associated with increased 
resistin levels [112]. Several studies have not detected a correlation between resistin and 
either prevalence or outcome of coronary disease [113-115]. This could be a result of 
ethnic variation or differences in study design and patient selection.  
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Visfatin and its relationship with obesity 
 
Fukuhara et al [37] identified a new novel adipose tissue cytokine called visfatin, 
a protein mediator secreted by fat cells (high levels of expression in visceral fat cells) 
which acts like an enzyme (Nicotinamide phosphoribosyl transferase) Nampt, which is 
involved in NAD+ salvage pathway. Initially it was identified as Pre B cell Colony 
Enhancing Factor (PBEF), secreted by human peripheral blood lymphocytes [116]. 
Visfatin has insulin-mimetic effect that was originally discovered in liver, skeletal 
muscle and bone marrow as a growth factor for B lymphocyte precursors [37, 117]. 
Circulating visfatin levels are closely correlated with WAT accumulation, visfatin 
mRNA levels increase in the course of adipocyte differentiation, and visfatin synthesis is 
regulated by several factors, including glucocorticoids, TNF, IL-6 and growth hormone. 
Visfatin is not only produced by WAT, but also by endotoxin challenged neutrophils, in 
which it prevents apoptosis through a mechanism mediated by caspases 3 and 8 [117]. 
Patients with inflammatory bowel diseases have elevated circulating visfatin levels and 
higher levels of visfatin mRNA in their intestinal epithelium. Visfatin has been shown to 
induce chemotaxis and the production of IL-1β, TNF, IL-6 and costimulatory molecules 
by CD14+ monocytes, and to increase their ability to induce alloproliferative responses 
in lymphocytes, effects which are mediated intracellularly by p38 and MEK1 [118]. 
High circulating visfatin levels have been observed in rheumatoid arthritis [119] and 
acute lung injury [120]. Significantly higher visfatin mRNA expression was found in 
inflamed Inflammatory Bowel Disease [118]. The binding affinity of 
visfatin/PBEF/Nampt to the IR (insulin receptor) was found to be similar compared with 
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that of insulin [37]. Many studies have demonstrated an increased level of visfatin in 
diabetes mellitus [42, 121, 122]. However, in an experiment conducted on cohort of 
obese patients, no correlation was found between PBEF/visfatin to glucose infusion 
[123]. Whether visfatin binds to the IR remains controversial. Whether visfatin binds to 
insulin receptors and exerts its insulin mimetic activity is still a controversy, but recent 
research has shown that Nampt/visfatin-mediated systemic NAD+ biosynthesis is 
necessary for β cell function, suggesting that visfatin helps in regulation of glucose 
homeostasis [124]. Circulating visfatin levels are closely correlated with WAT (White 
Adipose Tissue) accumulation, visfatin mRNA levels increase in the course of adipocyte 
differentiation, and visfatin synthesis is regulated by several factors, including 
glucocorticoids, TNF-α, IL 6, and GH [117]. Visfatin levels have been shown to be 
increased in children of more BMI indicating important implication of this new 
adipokine in inflammatory mechanisms of obesity starting already in childhood [125]. 
Visfatin were shown to be increased in females with obesity (visceral obesity) [37]. 
Decrease in circulating visfatin was found in morbidly obese women who lost more than 
20% of their BMI, also increased plasma visfatin concentrations in morbidly obese 
subjects are reduced after gastric banding [126]. These studies show that more the BMI 
(obesity), more the visfatin levels and visfatin levels decrease after weight loss. 
Interaction among inflammatory markers in obesity 
 
The incidence of obesity has dramatically increased and has become epidemic in 
United States. Obesity has multifactorial etiology which includes genetic, 
environmental, socioeconomic, and behavioral or psychological influences. Obesity is 
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the result of a chronic positive energy balance which is regulated by a complex 
interaction between endocrine tissues and the central nervous system [127, 128]. 
Adipocytes produce and secrete several proteins, collectively called adipokines which 
play important roles in the inflammation. These adipokines include TNF-α, leptin, IL-6, 
adiponectin, resistin and visfatin. Vendrell et al [129] conducted a study on fifty-seven 
morbidly obese white subjects with a mean age of 42.2±9.2 years (8 men and 49 women) 
and nonmorbidly obese subjects (117; mean age 49.2±12.4 years; 28 men and 89 
women). Descriptive statistics showed that morbidly obese subjects had higher values in 
all anthropometric measurements as compared to nonmorbidly obese patients which 
include BMI, waist to hip ratio and body fat. In the nonmorbidly obese group, significant 
differences were observed for leptin (13.3±7.0 vs. 34.2±13.4 ng/mL, p<0.001) and 
adiponectin (11.3±4.5 vs. 18.0±6.7 g/mL, p<0.001) in between men and women. There 
was significant gender difference for resistin.  
In nonmorbidly obese subjects, leptin correlated positively with BMI (r=0.390, 
p<0.01) while Adiponectin showed a strong negative correlation with weight (r=0.33, 
p=0.001), triglycerides (r=0.22, p=0.006), and fasting insulin (r=0.28, p=0.05) but a 
positive correlation with HDLc (r=0.36, p=0.001). Serum resistin was positively related 
to sTNFR1 (r=0.31, p=0.01) and triglycerides (r=0.24, p=0.01). In the morbidly obese 
group, leptin, adiponectin, and ghrelin did not correlate with any measurements of body 
composition. Resistin was found to correlate positively and significantly with weight 
(r=0.48, p<0.001), BMI (r=0.39, p<0.005) and fat-free mass (r=0.39, p<0.01). The 
findings for the bivariate correlation analyses were further explored using multivariate 
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analysis to control for potential confounders. After adjusting for age, gender, and BMI in 
nonmorbidly obese patients, leptin was positively related to gender and BMI (β=0.52, 
p<0.001 and β=0.24, p=0.009 respectively). Adiponectin was positively related with 
HDLc and gender (β=0.31, p=0.007 and β=0.22, p=0.05, respectively) and negatively 
associated with weight (β= -0.38, p<0.001). Resistin circulating levels were found to be 
positively associated with sTNFR1 after adjusting for the above-mentioned variables 
(β=0.28, p=0.007), losing the correlation with triglycerides observed in the bivariate 
analysis. None of these adipokines was found to be associated with clinical or metabolic 
variables in morbidly obese subjects except for the resistin and ghrelin levels that were 
positively correlated with sTNFR2 after adjusting for age, gender, and BMI (β=0.41, 
p=0.008 and β=0.33, p=0.04 respectively). 
Effects of diet-induced weight loss on resistin and visfatin 
 
Diet, exercise and diet plus exercise are different ways to lose weight. Weight 
loss also changes the perceptions of oneself and improves quality of life [130]. Weight 
loss and caloric restriction have been shown to improve insulin resistance and lipid 
profiles [131, 132]. Two longitudinal analyses revealed changes in serum resistin to be 
positively correlated with changes in fat mass or weight status [133, 134] and mean 
insulin [133], while other studies reported no changes of resistin in weight loss [129, 
135, 136]. Varady et al [137] has shown that decrease in body weight, as small as 5% 
from baseline, can improve circulating adipokines profiles and decrease adipocyte size 
in severely obese women. They reported an increase in the beneficial adipokines like 
adiponectin, and decreases in the less favorable adipokines, leptin and resistin, in women 
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who lost at least 5% of their initial body weight. This degree of weight loss also resulted 
in significant reductions in both subcutaneous and visceral fat cell size. Improvements in 
adipocyte physiology were associated with reductions in glucose and insulin, which may 
indicate protection from metabolic disease in this high risk population.  
Koebnick et al [138] conducted a 4 month diet-induced weight loss intervention 
in overweight individuals to investigate changes in resistin concentration and markers of 
glucose and lipid metabolism Results showed that there was a mean weight reduction of 
4.5 kg and significant increase in serum resistin level in overweight individuals. 
However, there was no direct association between resistin and insulin resistance in 
humans. Increase in serum resistin level contradicts the physiological understanding of 
resistin action based on previous mice experiments, where a strong relationship among 
adiposity, insulin resistance and resistin was observed [34, 93, 139]. Reinehr et al [140] 
conducted a study to assess changes in serum resistin levels before and after weight loss 
in obese children. Intervention period was for one year. Results showed no significant 
difference in serum resistin levels between obese and lean children. There was no 
significant correlation between resistin and insulin resistance index. Even though, obese 
children demonstrated significantly higher insulin resistance index (P<0.001) and insulin 
concentrations compared to the lean children; age, gender, pubertal stage, and resistin 
levels did not significantly differ between obese and lean children. At baseline, resistin 
serum concentrations did not significantly correlate to SDS-BMI, waist-to-hip ratio, 
percentage body fat, age, and HOMA. After the intervention period, there was a 
significant decrease in SDS-BMI by at least 0.5 (decrease in median 0.7, IQR 0.6– 0.9) 
28 
in 16 children out of the total participants. This degree of weight loss led to a significant 
decrease in insulin levels and HOMA but there were no significant changes in resistin 
levels. In the remaining 22 obese children with weight loss <0.5 SDS-BMI, there were 
no significant changes in insulin resistance index (HOMA), insulin, and resistin 
concentrations. 
A study conducted by Ho and colleagues [141] on 28 overweight and obese 
nondiabetic subjects (F: 15, M: 13, age 39±5 years, BMI 33.2±4.6 kg/m2) without any 
diseases where in participants underwent a one year calorie restricted weight loss 
intervention. After the intervention, participants achieved 9.4±6.9% weight loss, 
predominantly fat mass (7.7±5.6 kg, p<0.0001). Dietary intervention led to significant 
decrease in leptin, leptin-to-adiponectin ratio, and IL-6 (all p<0.02), and improvement in 
HOMA-IR and Insulin Sensitivity Index (SI) (both p<0.001). In response to weight loss 
IL-1β, IL-2, leptin, and resistin were significantly associated with insulin sensitivity. 
Table 2.1 provides a summary of some other studies that have done to look at the effects 
of exercise and/or dietary intervention on inflammatory marker, resistin. 
De Luis et al [142] conducted a two month study on 41 morbidly obese patients 
(mean age= 49.9±15.7 years and mean BMI=44.6±5.6 with 8 males (19.5%) and 33 
females (80.5%)) on a hypocaloric diet. Participants were on a mean caloric intake of 
1741.9±812.7 kcal/day (49% of carbohydrates, 28% of lipid and 23% of proteins). 
Results have shown that there was a weight loss of average 4.41% in morbidly obese 
patients leads to decrease in BMI, weight, fat mass, fat free mass, waist circumference, 
systolic blood pressure, serum glucose, total cholesterol, insulin and HOMA. However, 
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no significant decrease in visfatin concentration (43.5+30.8 vs. 47.1+38.1 ng/ml) was 
seen. In the multivariate analysis, visfatin as a dependent variable in the model before 
diet, and C reactive protein (CRP) as an independent predictor, it was found that there 
was an increase of 1.82 ng/ml (CI95%:0.02-3.61) basal visfatin concentrations with each 
increase of 1 mg/dl of CRP. HOMA was the only independent predictor in the model 
after diet. There was an increase of 11.4 ng/ml (CI95%:1.76-21.11) post treatment 
visfatin concentrations with each increase of 1 unit HOMA. There was no significant 
change in circulating visfatin concentration in morbidly obese patients after 2 months 
with weight reduction due to hypocaloric diet. 
De Luis and colleagues [155] have also conducted another 3 month study on 80 
obese non-diabetic patients, with 20 men and 60 women with BMI 34.1±4.8 kg/m2. 
After 3 months on a hypocaloric diet, they found that were decrease in BMI, fat mass, 
waist circumference, systolic blood pressure, fasting serum glucose, total cholesterol and 
low-density lipoprotein cholesterol. There was a significant change in visfatin level after 
weight loss in women (105±81 versus 90.9±40.1 ng/mL, P<0.05). In women, the 
association was observed with age (r = -0.2, P<0.05) and triacylglycerol concentration (r 
= -0.54, P<0.05). They did not find a significant correlation between visfatin 
concentration and anthropometric parameters, such as waist circumference, fat mass or 
lean mass. Agueda et al [156] has shown that changes in circulating serum visfatin levels 
were significantly and inversely associated with HOMA-IR (P < 0.01) after energy 
restricted diet intervention, regardless of achieved body weight loss. After energy 
restricted diet-induced weight loss, they did not find any significant association between
30 
Table 2.1 Some published data on the effects of exercise and/or dietary intervention on resistin 
Study, year No. of 
participants 
Duration General Findings Effects on 
Resistin 
Kadolgou et al 
[143] 
60 overweight/obese 
patients, BMI> 25 
kg/m2 
16 week, Aerobic 
exercise training 
versus control 
↓ A1C, ↓ Fasting plasma 
glucose, improvement in 
HOMA-IR, fasting insulin 
levels, systolic and diastolic 
 blood pressure and lipid 
profile
 
↓ resistin correlated 
with HsCRP, IL-18 
and VO2max 
Aghapour et al 
[144] 
20 postmenopausal 
women 
6 week aerobic 
training 
↓ Resistin 
Jamurtas et al 
[145] 
9 young overweight 
males, BMI 27-
32 kg/m2 
Acute exercise, 65% 
of their maximal 
oxygen consumption 
for 45 min 
No change in 
resistin up to 48 h 
post-exercise 
Jones et al 
[146] 
12 overweight/obese 
subjects, BMI 
31.8±5.2 
32 weeks, exercise 
training 
Significant ↓ in fat mass and 
percent body fat although 
weight, waist circumference, 
and BMI did not change 
8% decrease in post 
training resistin 
level. 
Significant 
correlation between 
resistin and 
triglyceride level. 
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Study, year No. of participants Duration General Findings Effects on Resistin 
Ozcan et al 
[147] 
40 overweight/obese 
women, BMI 
(Aerobic group = 
29.6 ± 0.79 Core 
group = 29.3 ± 0.49) 
16 weeks, Aerobic & 
core exercise 
significant decrease in fat 
mass and body weight 
(p<0.001) 
Significant decrease 
in resistin (21% in 
aerobic group & 
26.6% in core 
exercise group) 
Zhang et al [79] 9 men & 13 women 
overweight/obese 
Chinese women 
8 weeks, Slim 
exercise prescription 
Decrease in weight, BMI, 
waist & hip circumference, 
blood sugar 
↓ resistin 
Prestes et al 
[148] 
35 sedentary post-
menopausal women, 
Mean body mass 
57.84 kg 
16 weeks, periodized 
resistance training 
Reduce systemic 
inflammation 
↓ resistin 
Botero et al 
[149] 
23 post-menopausal 
overweight/obese 
women, 
Mean body mass 
67.56±2.26 kg 
12 month periodized 
resistance training 
Decrease in body mass, body 
fat mass 
↓ 44.9%  in resistin 
Table 2.1 continued 
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Study, year No. of participants Duration General Findings Effects on Resistin 
Bjersing et al 
[150] 
48 fibromyalgic 
overweight/obese 
patients. 9 patients 
were lean (BMI 18.5 
to 24.9), 26 
overweight (BMI 25 
to 29.9) and 13 obese 
15 weeks, exercise 
outdoor twice a 
week 
Increase in resistin 
after exercise period 
correlated with 
decreased fatigue 
Many et al 
[151] 
11 obese adolescents 
(BMI 41.4 ± 1.8 
kg/m2) 
8 weeks, aerobic 
exercise 
Reduction in BMI and percent 
total body fat 
14.5 ± 4.5% ↓ in 
resistin 
Buyukyazi et al 
[152] 
37 pre-menopausal 
women, BMI>27 for 
all groups 
High and moderate 
intensity walking 
and control groups, 
12 weeks for 5 days 
per week from 30-0 
min/day 
Decrease in body weight, 
percent body fat, BMI and 
waist circumference 
23.5% ↓ in resistin 
in high intensity 
walking group 
Izadpanah et al 
[153] 
21 overweight/obese 
children, BMI 33.0 ± 
1.8 kg/m2 
2 week, ad libitum, 
high-fiber, low-fat 
diet and daily 
exercise regimen 
No significant change in 
weight 
↓ resistin 
Table 2.1 continued 
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Study, year No. of participants Duration General Findings Effects on Resistin 
Ounis et al 
[154] 
27 female adolescent, 
BMI>97th percentile 
8 weeks, 3 groups: 
diet, individualize 
training and training 
combined with diet 
BMI by 6.1, 1.5, 11.5%, and 
%BF by 7.3, 3.6, 15.1% in 
diet, training and diet/training 
groups respectively 
20.3% ↑ in resistin 
in diet/exercise 
group 
Azuma et al 
[133] 
Sixty-four young (age 
32±10 years), obese 
(BMI 32.9±5.6), 
nondiabetic 
subjects taking no 
medication, and 15 
lean (BMI 21.1±1.3 
1.5 years, Weight 
reduction program 
entailing dieting and 
exercise 
Mean reduction in body 
weight of 4% 
Significant ↑ in 
resistin level in 
obese subjects than 
in lean volunteers 
(24.58±12.93 
ng/mL; n=64 vs. 
12.83±8.30 ng/mL; 
n=15; p<0.01 
positively correlated 
with BMI 
 Monzillo et al 
[136] 
24 obese  
BMI 36.7 ± 0.9 
26 weeks, 500 
kcal/day deficit 
energy-‐restricted 
diet & 
moderate-‐intensity 
exercise  
7.0% of weight No change in 
resistin 
↓ = significant reduction; BMI=Body Mass Index; A1C= glycosylated hemoglobin; HOMA-IR= Homeostasis Model Assessment of Insulin Resistance; HsCRP= Highly Sensitive C 
Reactive Protein; IL-6= Interleukin-6; VO2max= Maximal Oxygen Consumption; %BF = Body fat Percentage 
Table 2.1 continued 
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restricted diet-induced weight loss, they did not find any significant association between 
changes in visfatin levels and IL-1b, IL-6, IL-8, TNF-α and CRP levels (all P > 0.2). 
However, circulating visfatin concentration is associated with sensitivity improvement 
after the intervention. Furthermore, lean mass changes could be an influencing factor on 
visfatin concentrations and consequently, on the improvement of insulin sensitivity after 
weight loss in obese non-diabetic women. They did not provide any evidence for a role 
of visfatin increase on low-grade inflammation after weight loss. 
Kovacikova et al [157] conducted a dietary intervention study on 47 pre-
menopausal women (age 38·7 ± 1·7 years, range 25–57 years, BMI 27·9 ± 1·4 kg m–2, 
range 17·3–50·5 kg m-2). They divided the participants randomly into three different 
subgroups, lean (n =15), overweight (n = 16) and obese (n =16). Results showed that 
dietary intervention leads to decrease in body weight and BMI by 8%, body fat mass by 
16% and waist circumference by 9% in the entire group of 32 overweight/obese women. 
They also established that Visfatin mRNA expression in subcutaneous adipose tissue is 
associated with TNF-α expression, and BMI in pre-menopausal women. The 12 week 
hypocaloric weight reducing diet caused an increase of visfatin mRNA levels (P < 0·05) 
and tended to decrease visfatin plasma levels in the entire overweight/obese group (P < 
0·1). It is however notable that increase in visfatin gene expression did not reach 
significance in the subgroups of overweight or obese women, respectively. The 
relationship between the weight loss and the diet induced increase of visfatin mRNA 
expression was further supported by the finding of a positive correlation between these 
two variables in the whole overweight/obese group (r = 0·427, P < 0·05) and the 
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overweight subgroup. There was positive correlation between the diet induced changes 
of the expression of TNF-α and visfatin mRNA levels in subcutaneous adipose tissue in 
the whole overweight/obese group. Furthermore, there was a clear positive relationship 
between the magnitude of weight loss and the increase of visfatin mRNA levels. 
However, Visfatin expression is negatively related to body mass index and the diet 
induced weight reduction results in an increase of the visfatin expression in 
subcutaneous adipose tissue. Table 2.2 provides a summary of studies on the effects of 
dietary intervention on inflammatory marker, visfatin.  
Effects of exercise induced weight loss on inflammation and its markers 
 
Exercise improves many components of the cardiovascular risk factor profile 
especially endothelial function [158-162] which affects NO bioavailability. However not 
as well researched, it has been suggested that exercise may also improve levels of 
adipokines and oxidative stress. A large body of evidence exists suggesting that 
individuals who are either more physically active or more aerobically fit tend to have 
more favorable adipokine profiles and lower levels of oxidative stress [163-168]. 
However, most of these data are based on cross-sectional studies, and few studies have 
assessed the direct effects of exercise training on these variables. Many of the controlled 
intervention studies addressing this issue have shown that exercise improves adipokine 
and oxidative stress levels; however, most of these trials have reported concomitant 
improvements in body weight and/or composition that occurred during the exercise 
training period [27, 136, 169, 170] or did not include measures of body fat markers [171, 
172]. Because adipocytes are the main mediators of these hormones, changes in body 
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weight/composition confound the data concerning the direct effects of exercise on these 
variables. Recent studies have challenged the notion that exercise directly stimulates 
improvements in adipokines and inflammatory markers independent of weight loss [173-
175]. Although these studies are at odds with a large body of previous work, they 
provide a rationale for additional studies to be performed to further address this 
question.  
Effects of exercise induced weight loss on resistin  
 
Previous studies have shown mixed results on the effect of exercise induced 
weight loss on serum resistin level [136, 144, 145]. Aghapour et al [144] evaluated the 
effect of endurance exercise on resistin in old women aged 50-55 years, who performed 
6 weeks aerobic exercise, three times a week for 45 minutes each session at 50% 
maximum heart rate reserve during the first week and 60 minutes of exercise at the sixth 
week with 60% of maximum heart rate. There was 5% intensity of aerobic activity added 
every two weeks. They showed that regular aerobic activity can reduce levels of resistin 
in human indicating the decline of inflammation even though there was no significant 
difference in resistin level before and after 6 weeks of aerobic exercise period.  
 Jamurtas and their colleagues [145] conducted study on nine young overweight 
males exercised for 45 minute at an intensity corresponding to 65% of VO2max. Subjects 
were instructed to follow their normal eating pattern. They reported relatively stable
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Table 2.2 Some published data on the effects of dietary intervention on visfatin 
BMI=Body Mass Index; HOMA-IR= Homeostasis Model Assessment of Insulin Resistance 
Study, Year Number of 
Participants 
Duration General Findings Effects on Visfatin 
Agueda et al 
[156] 
78 obese (BMI 
34.0 ± 2.8 kg/m2) 
women  
12 weeks of energy 
restricted diet 
intervention 
Mean weight loss 7.7 ± 3.0 kg 
and HOMA-IR decreased 
Significant 11.9% ↑ 
in visfatin level and 
inversely associated 
with HOMA-IR 
(P < 0.01) 
De Luis et al 
[142] 
41 obese patients, 
BMI>40 kg/m2 
2 months 
Hypocaloric diet 
Weight loss (average 4.41%) No change in 
visfatin,  
De Luis et al 
[155] 
80 obese men 
(20)/women (60), 
BMI 34.1 ± 4.8 
kg/m2 
3 month 
Hypocaloric diet 
↓ in body mass index, fat mass, 
waist circumference 
Significant 11.4 % ↓ 
in visfatin 
Kovacikova 
et al [157] 
 47 
overweight/obese 
women, BMI 
27·9 ± 1·4 kg m−2 
12 week 
Hypocaloric diet 
↓ in body weight Significant 60% ↓ in 
visfatin in 
overweight group 
only 
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levels of resistin after acute exercise. This finding is in accordance with the available 
chronic exercise studies that did not find alterations in the levels of the hormone after 
aerobic training for several months [136, 176].     
Jones and colleagues [146] conducted a 32 weeks study on sedentary overweight 
adolescents. Participants underwent for an aerobic exercise for 45 minutes session, 3 
times per week at an intensity of 60-85% of measured VO2 max. Results showed that there 
was significant decrease in fat mass and percent body fat although weight, waist 
circumference, and BMI did not change. There was 8% decrease in post training resistin 
level and significant decrease in triglyceride concentration (23%). There was a 
significant correlation between resistin and triglyceride level. Ozcan et al [147] 
conducted a study on 40 sedentary middle aged women, randomly assigned into two 
groups, aerobic and core exercise. The exercise programs were performed 4 days a week 
for 16 weeks. Results showed that 16 weeks of  exercise leads to significant decrease in 
fat mass and body weight (p<0.001) and resistin levels (21% in aerobic exercise group 
and 26.6% in core exercise group, p<0.05). 
Another group of researchers [177] looked at the effect of exercise for 8 weeks 
on body fat mass, blood sugar and plasma resistin on overweight and obese individuals 
in Chinese population. Subjects consist of 9 men and 13 women, trained at the intensity 
of 60%-70% of functional capacity, 5 times per week for 60 minutes per session. Results 
showed that weight, BMI, body fay %, waist and hip circumference at indexes were 
significantly decreased (P<0.01). Plasms resistin level was significantly different for 
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men (P<0.01) and for women (P<0.05) as well. Furthermore, plasma resistin and BMI, 
waist and hip circumference have significant correlation for men but not for women.  
Prestes et al [148] conducted a study on 35 sedentary women post-menopausal 
(mean age 63.18 years, s=4.8; height 1.64 m, s=0.07; body mass 57.84 kg, s=7.70). 
Subjects underwent 16 weeks of periodized resistance training consisted of two weekly 
sessions of three sets of 6–14 repetition maximum. There was a decrease in resistin after 
24 and 48 h compared with baseline and a decline in baseline and immediately after 
levels compared with pre-training. Above mentioned results could be explained by the 
lower production of pro-inflammatory cytokines by the innate immune system. 
Periodized resistance training seems to be an important intervention to reduce systemic 
inflammation in sedentary women. 
Botero and coworkers [149] demonstrated an effects of long term periodized 
resistance training on body composition, muscle strength and resistin in elderly post-
menopausal women. 23 post-menopausal women (age= 63.02±4.42 years; height 
1.55±0.06 m; body mass 67.56±2.26 kg) underwent periodized resistance training twice 
a week for 12 months. The training protocol consisted of 3 sets of 6-14 repetitions 
maximal (RM).  Results showed that there was a significant increase in muscle strength 
and lean body mass and significant decrease in body mass, body fat percentage, fat mass 
and plasma resistin level after resistance training period. Bjersing et al [150] showed that 
in fibromyalgic patients, increase in resistin led to decreased fatigue which showed the 
beneficial effect of resistin. Another study demonstrated the benefit of moderate 
intensity aerobic exercise training for 8 weeks at an intensity of 40-55% nearly 180 
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minutes per week improved insulin sensitivity and led to decrease in resistin level [151]. 
Table 2.3 provides a summary of studies on the effects of exercise on inflammatory 
marker, resistin.  
Effects of exercise induced weight loss on visfatin 
 
Visfatin is an adipokine being mainly produced in visceral adipose tissue, also by 
cells, neutrophils and macrophages, and, furthermore, its plasma level correlates with the 
quantity of visceral fat in humans [37, 179]; however, the studies examining the effect of 
exercise on circulating visfatin levels are limited and often ambiguous. On the other 
hand, Buyukyazı et al [152]  have found no significant change in the visfatin 
concentration in obese women (30–49 years) in moderate-intensity walking program. 
Pagano et al. [40] have reported that visfatin levels were lower in subcutaneous fat 
locations and higher in visceral adipose tissue of the obese subjects compared to lean 
individuals. 
Berndt et al [123] have not reported any significant relationships between visfatin 
levels and the amounts of visceral adipose tissue as determined by CT measurements. A 
positive correlation between visceral adipose tissue visfatin gene expression and body 
mass index (BMI) had been found, but the relationship between subcutaneous fat visfatin 
and BMI was negative suggesting that visfatin regulation may differ depending on 
different fat patterns [41]. It could be concluded that changes in circulating visfatin 
levels are involved in the improvement of metabolic status by exercise and may be 
useful markers for exercise evaluation and prescription. 
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Table 2.3 Some published data on the effects of exercise on resistin 
 
 
Study, year 
 
No. of participants 
 
Duration 
 
General findings 
 
Effects on Resistin 
Valsamakis et al 
[134] 
41 overweight/obese 
women, BMI 46 ± 
8.6 kg/m2 
 
6 months, 
Treated with 
Sibutramine 
Mean weight loss of 5.4%, 
& waist circumference was 
reduced by 4.5 ± 1.4 cm 
Significant 16.8% ↓ in 
resistin; Change in waist 
was associated with 
change in resistin. 
Ho et al [141] 28 overweight/obese 
men (15)/women (13) 
BMI 33.2±4.6 kg/m2 
12 months, 
calorie 
restriction with 
behavioral 
support 
 
9.4±6.9% weight loss, 
mostly fat mass 
resistin were significantly 
associated with insulin, 
sensitivity 
Varady et al 
[137] 
13 obese women, 
body mass index, 50 
± 3 kg/m2 
3 weeks,  low-
calorie diet 
Decrease in body weight Non-significant 11.6% ↓ 
in resistin in <5% weight 
loss group & significant 
27.4% ↓ in resistin in 5%-
10% weight loss group 
 
Koebnick et al 
[138] 
50 overweight/obese 
women BMI >25 
kg/m2 
4 month, Dietary 
intervention 
Overweight subjects lost 
4.570.6 kg body weight 
and 3.370.6% body fat 
19.4% ↑ in resistin & 
inversely related to 
changes in waist-to-hip 
ratio and positively to 
serum apolipoprotein B, 
HOMA-IR, NEFA 
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Study, year No. of participants Duration General findings Effects on Resistin 
Lopez et al 
[178] 
70 obese healthy 
subjects, BMI >27 
kg/ m2 
8 weeks, 
Supplementation 
with multi-
ingredient 
weight loss 
product 
Decrease in body weight, 
fat mass, lean mass, waist 
girth, hip girth 
Non-significant 15.8% ↓ 
in resistin in METABO 
group 
Reinehr et al 
[140] 
63 obese children vs 
36 lean children 
1 year, Weight 
reduction 
through 
“Obedicks’ 
intervention” 
↓ body weight in obese 
children 
No change in resistin,  
No significant correlations 
between changes of 
resistin and changes of 
SDS-BMI, changes of % 
body fat, changes of waist-
to-hip ratio and changes of 
insulin resistance index  
BMI= Body Mass Index; HOMA-IR= HOMA-IR= Homeostasis Model Assessment of Insulin Resistance; NEFA= Non-esterified Fatty Acid; METABO= multi-ingredient supplement 
containing primarily raspberry ketone, caffeine, capsaicin, garlic, ginger and Citrus aurantium
Table 2.3 continued 
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 Walhin and cowokers [180] investigated the effects of short term overfeeding 
and decreased physical activity independent of energy imbalance in healthy young men. 
26 active young men age 25±7 years were randomly assigned into two groups; one who 
consumed 50% more calorie diet an restricting their physical activity, another without 
any intervention. Result has shown that there was a significant down-regulation of 
visfatin in the group with intervention as compared to the control. Vigorous intense 
activity counteracted this effect even the participants has standardized energy surplus. 
Another study conducted by Rudwill et al [181] demonstrated a negative association of 
visfatin with activity energy expenditure and no relationship with insulin sensitivity. 
Another group of researchers compared the effect of aerobic exercise and aerobic 
combined with resistance exercise. They found that both aerobic exercise and aerobic 
combined with resistance exercise decrease visfatin level but there was no significant 
difference in the magnitude within and between group comparisons [182]. Table 2.4 
provides a summary of studies on the effects of exercise training and/or dietary 
intervention on inflammatory marker, visfatin.  
Effects of diet and exercise induced weight loss on inflammatory markers 
 
 A study conducted by Lopez and coworkers [178] on 70 obese healthy subjects 
divided participants into two groups, placebo and METABO. Subjects in METABO 
group underwent 8 weeks of daily supplementation, a calorie restricted diet and exercise 
training. Significant differences were observed in body weight (METABO -2.0% vs. 
placebo -0.5%, P < 0.01), fat mass (METABO -7.8 vs. placebo -2.8%, P < 0.001), lean 
mass (METABO +3.4% vs. placebo +0.8%, P < 0.03), waist girth (METABO -2.0% vs. 
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placebo -0.2%, P < 0.0007) and hip girth (METABO -1.7% vs. placebo -0.4%, 
P < 0.003). There was a decrease in serum resistin (P < 0.08). All these above mentioned 
significant results could be due to the effect of diet, exercise or both.  
Another study conducted by Elloumi et al [17] on 21 obese adolescent boys 
(BMI = 30.8 ± 3.2 kg ⁄ m2), participated in one of the weight loss program, energy 
restricted, individualized exercise training or energy restricted and training for 2 months. 
After the training period completion, combined group showed a significant improvement 
in body composition (p<0.01). Both, exercise and combined group showed a significant 
increase in resistin level (p<0.05). There was also a significant correlation between an 
increased ratio of adiponectin/leptin and resistin level. They concluded that energy 
restriction improved the ability to better oxidize lipids which was associated with 
normalization of inflammatory markers such as adiponectin, leptin and resistin.  
Izadpanah and colleagues [153] examined the effect of short term diet and 
exercise intervention on inflammation and markers of metabolic syndrome. They had 21 
overweight/obese children (9 boys/12 girls, age 13.0 ± 0.5 yr, BMI 33.0 ± 1.8 kg/m2) 
were placed on ad libitum, high-fiber, low-fat diet and daily exercise regimen for 2 wk. 
They found that there was a decrease in resistin level along with IL-6, leptin, insulin and 
TNF-α even though there was no significant weight loss. They were among the few 
researchers who showed the correlations of inflammatory makers with fatty acid. They 
also revealed that there was negative correlation of inflammatory markers with a cluster 
of polyunsaturated fatty acids and positive correlation with saturated fatty acids.   
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Table 2.4 Some published data on the effects of exercise training and/or dietary intervention with exercise on visfatin 
Study, year No. of participants Duration General Findings Effects on 
Visfatin 
Rudwill et al [181] 33 healthy subjects, 
BMI 23.4 ± 0.6 kg·m−2 
3 months long, 
Induction of physical 
inactivity 
Decrease in fat free mass 
and body mass 
54.9% & 49.7% ↑ in 
visfatin in 10 days 
confinement and 3 
months bed rest 
groups respectively 
Frydelund et al [179] 15 healthy young men, 
BMI 24.9 ± 2 kg/m2
Acute exercise, 3 h f 
cycling at 60% 
VO2max followed by 6 
h of recovery 
No change in 
visfatin level 
Haider et al [183] 18 patients with type 1 
diabetes, BMI 28.5 ± 
5.2 kg/m2
 4 months aerobic 
exercise  
Significant 98.4% ↓ 
in visfatin after 4 
months of training 
Buyukyazi et al [152] 37 pre-menopausal 
women, BMI (High 
intensity group-
28.2±4.4, Moderate 
intensity group-
29.3±2.5, Control 
group-27.3±4.9) 
High and moderate 
intensity walking and 
control groups, 12 
weeks for 5 days per 
week from 30-0 
min/day 
Decrease in body weight, 
percent body fat, BMI 
and waist circumference 
↓ visfatin in high 
intensity walking 
group 
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Study, year No. of participants Duration General Findings Effects on 
Visfatin 
Kadoglou et al [182] 100 patient with type-2 
diabetes, BMI>25 
kg/m2 
4 weeks, aerobic and 
aerobic + resistance 
exercise 
No significant changes in 
anthropometric measures 
↓ visfatin 
Choi et al [184] 48 overweight/obese 
women, BMI≥25 
kg/m2 
12 week exercise, 
aerobic and muscle 
strength training 
Visfatin levels were 
associated with BMI 
(R2 = 0.255) and eotaxin 
levels were associated 
with WC and body weight 
(R2 = 0.307) 
43.4% ↓ in visfatin 
levels (13.6 ± 12.0 
to 7.7 ± 7.9 ng/ml) 
Walhin et al [180] 26  healthy young men, 
BMI 23.8 ± 2.5 kg m−2 
Two groups, Energy 
surplus and surplus 
+exercise. one had 45 
min of daily treadmill 
running at 70% of 
maximum oxygen 
uptake and another 
group restricting their 
physical activity 
Body mass, waist and hip 
circumference and lean 
mass were significantly 
increased at follow-up in 
both groups 
Visfatin was down 
regulated in surplus 
group but no change 
in exercise and 
surplus 
Table 2.4 continued 
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Table 2.4 continued 
Study, year No. of participants Duration General Findings Effects on 
Visfatin 
Sheu et al [185] 21 obese women with 
BMI 32.5 ± 1.2 kg/m2
Versus 10 lean women 
served as controls  
12-week caloric 
restriction and light 
exercise-based weight 
loss program 
Significant reductions in 
BMI, fasting glucose and 
insulin concentrations, 
mean serum high-
sensitivity C-reactive 
protein (hs-CRP), 
migration inhibitor factor 
(MIF), leptin and visfatin 
levels decreased by 49.0, 
66.6, 17.2, and 50.2%, 
respectively  
Significant 50.2% ↓ 
in visfatin after 
weight loss 
BMI=   Body mass Index; VO2max= Maximal Oxygen Consumption
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Ounis et al [154] conducted a study on twenty seven 13 year old female 
adolescents with BMI greater than 97th percentile. They were divided into 3 groups: diet, 
individualize training and training combined with diet. After the 8 week intervention, 
there was decrease in BMI by 6.1, 1.5, 11.5%, and %BF by 7.3, 3.6, 15.1% in diet, 
training and diet/training groups respectively. Diet/training group had a significant 
decrease in leptin, TNF-α and IL-6, and a significant increase in adiponectin and resistin. 
The post program usual index of insulin resistance (HOMA-IR) was significantly 
improved in training (p < 0.05) and diet/training (p < 0.01) groups. Diet group did not 
present a significant reduction in HOMA-IR. The most important effect of these 
interventions of food intake and exercise was weight loss which led to improvement of 
body image. In this study, changes in resistin level were significantly correlated with 
changes in insulin sensitivity. The data supported the hypothesis that resistin opposes the 
insulin action and decrease of resistin is associated with improvement of insulin 
sensitivity.  
Based on the numerous studies conducted in the past on overweight/obese 
women, combination of diet and exercise always results in the best reduction of body 
weight, probably with a greater negative energetic balance as compared to just diet or 
exercise intervention.  
Conclusion 
Metabolic homeostasis is maintained by multiple organ systems. Adipose tissue 
and muscles are a few of them. Adipocytes secrete hormones/chemicals known as 
adipokines which act on multiple cells or organs to regulate metabolism. The 
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understanding of the concentrations of these hormones in children, adolescents and 
adults including elderly and overweight/obese people as well as the role they may play 
in obesity, metabolic syndrome, diabetes, coronary, atherosclerotic diseases, 
hypertension etc. is imperative. It is also important to understand how lifestyle choices 
such as dietary intervention, regular exercise (aerobic or resistance), supplementation or 
combination of any of these affect adipokines/hormones concentrations so there is a 
better insight into their regulation and pathophysiology. Roles of resistin and visfatin in 
metabolism/homeostasis are not completely understood; given the interest in these 
hormones remain high. There are a very few studies published so far that have 
investigated the impact of weight loss on resistin and visfatin expression in a 
longitudinal study on sedentary obese healthy women. The purpose of this study is to 
examine the combined effects of exercise and diet-induced weight loss on markers of 
health and inflammation such as resistin and visfatin and their interactions among each 
other. The results of this study will provide additional information and data evaluating 
whether exercise and diet-induced weight loss affects inflammatory markers such as 
resistin and visfatin and their association with other anthropometric and inflammatory 
markers that will eventually provide an insight to better understand the inflammatory 
mechanism related to obesity and metabolic syndrome. We believe that this exercise and 
diet-induced weight loss program would alter these markers. This study will compare the 
results of overweight/obese population to control group.  
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CHAPTER III 
METHODS AND MATERIALS 
Study design and site 
Data for this study were obtained from a large comparative effectiveness study 
evaluating different weight loss program approaches. Subjects were randomly assigned 
into non-exercise and non-diet control group (C) or an exercise and weight loss group 
(DE). This study was conducted for 90-days. In this study, all the subjects had a baseline 
testing session and post-training 12 week testing session (0 & 12 wk). Both the sessions 
included exercise testing. Exercise and diet-induced weight loss was the independent 
variable while body composition (body weight, fat mass, fat free mass and body fat 
percent), resistin, visfatin, glucose, insulin, leptin, TNF-α, IL-6, triglyceride and total 
cholesterol; maximum repetition 1(RM) and 80% 1RM isotonic strength were the 
dependent variables. Table 3.1 below shows the overall research design, time course for 
assessments, summary of the research design and the testing schedule for our 12 wk 
study program. Exercise & Sport Nutrition Laboratory (ESNL) in the Department of 
Health, and Kinesiology at Texas A&M University was the study site where all 
familiarization, testing, exercise training and assays were conducted.  
Participants and familiarization sessions 
Twenty six (26) overweight/obese sedentary women subjects (BMI > 27) 
between the ages of 18-65 were recruited to participate in this portion of the study. 
Participants with a history of electrolyte abnormalities, uncontrolled metabolic disorder, 
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arrhythmias, heart disease, diabetes, or thyroid disease; a history of hypertension, 
musculoskeletal, autoimmune, hepatorenal, or neurological disease were excluded from 
participation in the study. Other exclusion criteria included use of any hypoglycemic, or 
androgenic medications; and/or, ergogenic levels of nutritional supplements that may 
affect muscle mass (e.g., Creatine, HMB), anabolic/catabolic hormone levels (e.g., 
DHEA), or weight loss (e.g., Thermogenics) within three months prior to the start of the 
study. Participants with a controlled medical condition had their physician complete and 
sign a physician consent form prior to participation in the study. 
Participants who met eligibility criteria of our study program were informed of 
the requirements of the study and requested to sign consent statements in compliance 
with the Human Participants Guidelines of Texas A&M University and the American 
College of Sports Medicine. 
Individuals showing interest in the study were interviewed by phone to determine 
whether or not they were qualified to participate. The participants who met the eligibility 
criteria were invited to attend a familiarization session. During this session, participants 
received verbal and written explanation of the study protocol and design. Participants 
also received information about testing procedures, blood collection procedures and 
were introduced to the equipment that would be used for the 12 wk study period.  
Randomization 
 
Participants were then randomized according to body mass index (BMI) and age 
into two groups:  an exercise and diet-induced weight loss (DE) group or a control (C) 
group. 
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Table 3.1 Overview of research design and testing schedule 
 
Familiarization and Entry  
 
0 week 
(Baseline) 
12 weeks  
Phone interview  
 
 
Familiarization session  
 
Complete of paper work  
 
 
 
Review medical history  
 
 
Randomization into exercise 
and diet-induced weight loss 
and control programs  
High Protein Diet Review  
 
Body Weight  
 
 
Blood collection (white blood 
cells/serum)  
 
 
Dual Energy  
X-ray  
 
 
Absorptiometry (DEXA)  
 
Graded Exercise Testing 
(GXT)  
 
 
1RM at 80%  
1RM Isotonic Bench and  
Isotonic Leg Press  
 
30 minutes Resistance 
Exercise/Zumba  
4 times/week  
High Protein Diet Review  
 
Body Weight  
 
 
Blood collection (white blood 
cells/serum)  
 
 
Dual Energy  
X-ray  
 
 
Absorptiometry (DEXA)  
 
Graded Exercise Testing 
(GXT)  
 
 
1RM at80%  
1RM Isotonic Bench and  
Isotonic Leg Press  
 
30 minutes Resistance 
Exercise/Zumba  
4 times/week  
 
DEXA= Dual energy X-ray absorptiometry 
 
Diet intervention 
 
In the diet intervention program, subjects were instructed to follow Curves 
International (Waco, TX) Curves Complete high protein diet plan.  The diet was 
implemented in two phases. First phase of the study includes higher protein weight loss 
diet (1,200 kcals/day) for one week and the second phase includes higher protein weight 
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loss diet (1,500 kcals/day) for 11 weeks. There were same micronutrient content: 45% 
protein, 30% carbohydrate, 25% fat in both phases of the study. Participants were 
encouraged to take multivitamins and minerals containing 800 mg of calcium and 520 
mg of Omega-3 fatty acids everyday with food. A registered dietitian also met with 
subjects once a week throughout the study to discuss any dietary challenges or concerns 
and reviewed the higher protein diet (HPD), exercise and fitness and weight 
management plan provided to the participants along with food & exercise diary and 
Essentials-2-go dietary supplements. The Fitness and Weight Management Plan dietary 
intervention protocol is summarized in Table 3.2. 
Training protocol  
 
Subjects were randomized into the exercise and diet-induced weight loss group 
(DE) and control group (C). Subjects in DE group followed the Curves™ training 
program while subjects in the C group followed their normal eating and daily activities 
with no exercise. Subjects in DE group who underwent three regular resistance workouts 
each week for 12 weeks and one Zumba dance workout maintaining a greater than 90% 
compliance record (43 out of 48 workouts) were included in the physical training 
program. The circuit training platform utilized the computerized Curves Smart system. 
The smart system used the software designed by MYTRAK (version 4.2.1, copyright 
2004-2011, MYTRAK Health System Inc, Mississauga, Ontario, Canada). The circuit 
training equipment was set in the Exercise and Sports Nutrition Laboratory at Texas 
A&M University. The circuit based exercise training comprising of 13 bi-directional 
hydraulic resistance exercise machines worked all major muscle groups (i.e., elbow 
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flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, 
chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, 
chest flies, oblique, shoulder shrug/dip, hip extension, and side bends). During the 
training period, subjects were coached to perform as many repetitions as possible within 
30-second time period on each resistance machine. Between machines, subjects 
performed floor-based aerobic exercises or stepping exercise between machines. It was 
done to maintain an increased heart rate. Subjects completed the entire circuit twice 
during the 26 minute regular circuit workout. During the Curves Zumba workout, 
subjects performed 1 minute of Zumba dance moves as taught by a certified Zumba 
instructor. The circuit training sessions were supervised by trained fitness instructors. 
The instructors aided the subjects with appropriate exercise technique and self-
monitoring of heart rate so as to maintain heart rate between 60-80% of target heart rate 
using age-predicted maximal heart rate (220-age). Subjects also completed 4 minutes of 
whole body stretching following circuit workouts and were also encouraged to walk for 
30 min at a brisk pace at 60-80% of target heart rate on one of the days when they were 
not using the curves equipment.  
Testing methods 
 
Participants were instructed to refrain from exercising for 48 hours and fasting 
for 12 hours prior to baseline testing. Participants reported to the ESNL for assessment 
of body composition and clinical assessments followed by completing a radiation 
questionnaire. Participants were measured for weight, assessed for body composition by 
using Dual Energy X-ray Absorptiometry (DEXA) and their blood samples were 
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collected. In addition, they were taught to perform cardiopulmonary symptom-limited 
maximal exercise stress test; and, perform 1 repetition maximum (RM) and 80% of 1RM 
on the isotonic bench press and leg press.  
 
Table 3.2 Overview of diet assignments 
Diet 
Period  
Group              Macro-
nutrient 
Grams/ 
Day  
Kilocals/Day         Percent 
Daily     
Diet (%) 
Dietary  
Phase  
Exercise and diet-Induced Weight Loss (EX) Group (n=29) 
Phase I (1 
Week)  
1,200 
kcals/d  
Diet 
Intervention 
+ Exercise  
PRO  
CHO  
FAT  
135  
90  
33  
540  
360  
300  
45  
30  
25 
  
Phase II  
(11 weeks)  
1,500 
kcals/d  
Diet 
Intervention 
+ Exercise 
  
PRO  
CHO  
FAT  
169  
113  
42  
675  
450  
375  
45  
30  
25 
 
  Control ( C) Group (n=20) 
Baseline to 
12 Weeks  
Normal Diet  
Normal Activity  
No Exercise  None None None None 
PRO=Protein; CHO= Carbohydrate 
 
Body composition  
 
Standard anthropometry was used to measure height. Healthometer (Bridgeview, 
IL, USA) self-calibrating digital scale with a precision of +/-0.02 kg was used to 
determine total body weight. Hologic Discovery W QDR series DEXA (Hologic Inc, 
Waltham, MA, USA) equipped with APEX software (APEX Corporation Software, 
 56 
 
Pittsburgh, PA, USA) was used to measure body composition. Participants were 
informed of any or all inherent hazards that could result from the radiation exposure and 
completed a radiation exposure questionnaire prior to all scans. Before each testing 
session quality control (QC) calibration procedures were performed on a spine phantom 
(Discovery W-CALIBER Model DPA/QDR-1 anthropometric spine phantom). The 
DEXA has been validated as an accurate method for assessing body composition [186, 
187]. The mean test-retest reliability of studies performed on a few male athletes with 
this Hologic system yielded mean coefficients of variation for total bone mineral content 
and total fat free/soft tissue mass of 0.31% to 0.45% with a mean intra-class correlation 
of 0.985 [186].  
Cardiopulmonary exercise tests  
 
Cardiopulmonary exercise tests were performed at baseline and at 12 weeks 
using the standard procedures described by the American College of Sports Medicine’s 
(ACSM) Guidelines for Exercise Testing and Prescription,  [188]. Heart function was 
evaluated by the Nasiff Cardio Card electrocardiograph (Nasiff Associates, Inc, Central 
Square, NY, USA) using a standard 12-lead arrangement. Parvo Medics TrueMax 2400 
Metabolic Measurement System (ParvoMedics, Inc., Sandy, UT) was used to assess 
cardiopulmonary measurements.  
Following the speeds and inclination grades of the Parvo Medics TrueMax 2400 
Metabolic Measurement System (ParvoMedics, Inc., Sandy, UT), the participants 
completed the Bruce or modified Bruce treadmill protocol [189]. Continuous monitoring 
of heart rate (HR), electrocardiographic tracings, and expired gases were carried out 
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throughout the exercise test. At the end of each stage, blood pressure (BP) and ratings of 
perceived exertion (RPE) were measured. The participants were instructed to exercise to 
their maximum unless they experienced clinical signs requiring test termination As 
stated by the ACSM’s Guidelines for Exercise Testing and Prescription, participants 
were  advised to exercise to their maximum except in events of experiencing clinical 
signs that required test termination [190]. Applying the Bruce or modified Bruce 
protocol, the mean coefficient of variation for assessing peak Vo2 was found to be 6.5% 
(range, 2.0-14%). Determination of maximal aerobic capacity and anaerobic threshold, 
and thus measurement the effects of exercise and diet-induced weight loss training on 
markers of health and fitness on exercise capacity was the purpose of this test.  
Isotonic strength tests 
 
In the exercise and diet-induced weight loss program, participants’ in DE group 
1RM was determined using an isotonic Olympic bench press (Nebula Fitness, Versailles, 
OH, USA) and a standard hip sled/leg press (Nebula Fitness, Versailles, OH, USA). This 
was to observe changes in maximal strength according to standardized procedures. 
Standardization between trails was ensured by hand positioning on the bench press and 
foot and seat position on the hip sled/leg press. Using standard lifting techniques and 
testing criteria, muscular endurance was assessed by participants performing as many 
repetitions as possible at 80% of their predetermined 1RM on the bench press and leg 
press.  
Using standard procedures and under the supervision of certified lab assistants 
experienced in conducting strength exercise testing, all strength/exercise tests were 
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executed. Participants were assessed for upper body strength and endurance. They did 
one repetition maximum (1RM) test on the isotonic bench press and the Nebula Fitness 
(Versailles, OH, USA) Olympic Power Station (#1005), and a warm-up (2 sets of 10 
repetitions at approximately 50% of anticipated 1RM). The bench press and the warm-up 
were followed by progressive lifts starting at about 70% of anticipated 1RM and 
increasing by 5–10 lbs. until 1 RM was reached. Once the 1RM was achieved, 
participants performed as many repetitions as possible with 80% of their 1 RM efforts. 
Participants relaxed for 4 minutes, and then underwent a warm up 8-10 times at 
approximately 50% of anticipated maximum on the Nebula 45° Leg press. Starting at 
about 70% of anticipated 1RM and increasing by 10–25 lbs. until 1RM was achieved, 
participants performed successive lifts on the leg press. Once the 1RM was reached, 
subjects performed the lifts repeatedly and as many as possible with 80% of their 1 RM 
efforts. Test-retest reliability of carrying out these strength tests on resistance-trained 
subjects in our lab has shown low mean coefficients of variation and high reliability for 
the bench press (1.9%, intraclass r = 0.94) and leg press/hip sled (0.7%, intraclass r = 
0.91).  
Blood collection and analysis  
 
From each participant, approximately 2 teaspoons of fasting venous blood (10 
milliliters) were obtained. Adhering to standard phlebotomy procedures, blood samples 
were collected using standard sterile venipuncture of an antecubital vein by ESNL 
laboratory technicians or graduate research assistants proficient in phlebotomy. Blood 
collection procedures were in compliance with guidelines laid down by the Texas 
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Department of Health and Human Services. While collecting and handling blood 
samples, the phlebotomists and lab technicians wore personal protective clothing 
(gloves, lab coats, etc.). From each participant, about 10 ml of whole blood were 
collected in EDTA tubes. The EDTA tube contains a gel that helps in formation of 
physical barrier between serum, white blood cells (buffy coat) and red blood cells during 
centrifugation. To spin down the blood cells, BD Vacutainer® SST™ Serum Separation 
Tubes were centrifuged immediately at 1,200g for 15min at 4oC after blood collection. 
The supernatant (serum) were then shifted into two 1.5ml microcentrifuge tubes, 
followed by transferring the intermediate white layer or WBC (buffy coat) using a 
plastic 3 ml transfer pipette into labeled 1.5 ml Eppendorf tubes. Serum blood samples 
were sent to Quest Diagnostics (Houston, TX). Using an Olympus AAU 5400 Chemistry 
Immuno Analyzer (Olympus America Inc., Center Valley, PA), the blood samples were 
analyzed for comprehensive metabolic panel analysis. Using an Abbott Cell Dyn 3500 
automated hematology analyzer (Abbott Laboratories, Abbott Park, IL) whole blood 
samples were examined for complete blood counts with platelet differentials. Reported 
test-retest reliability of carrying out these assays generally range from 2 to 6% for 
individual assays. Samples were run in duplicate to ascertain if the observed values were 
above control values and/or clinical norms in accordance to standard procedures. The 
serum and white blood cells (buffy coat) were then aliquoted and stored at -80C until 
analyzed for the blood lipid panel (Triglyceride, HDL, LDL and total cholesterol) and 
inflammatory markers- resistin and visfatin.  
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Hormone analysis 
 
Blood samples were analyzed to detect human resistin by using enzyme-linked 
immunosorbent assay for quantitative detention. Human resistin platinum ELISA kits 
(BMS2040) were purchased from Affymetrix Ebiosciences (Santa Clara, California, 
USA). Kits were stored at temperature 80oC. Human Visfatin ELISA kits (RAB0377) 
were purchased from Sigma-Aldrich (St. Louis, Montana, USA). Resistin and visfatin 
kits were stored at temperature 80oC. The resistin and visfatin Enzyme Immunoassay 
(EIA) Kits are an in vitro quantitative assay for detecting resistin and visfatin peptides 
respectively based on the principle of competitive enzyme immunoassay. The microplate 
in the kit is pre-coated with anti-rabbit secondary antibody. After a blocking step and 
incubation of the plate with anti-peptide antibody, both biotinylated resistin/visfatin 
peptide, and peptide standard or targeted peptide in samples interacts competitively with 
the resistin/visfatin antibody. Uncompeted (bound) biotinylated resistin/visfatin peptide 
then interacts with Streptavidin-horseradish peroxidase (SA-HRP), which catalyzes a 
color development reaction. The intensity of colorimetric signal is directly proportional 
to the amount of biotinylated peptide SA-HRP complex and inversely proportional to the 
amount of resistin/visfatin peptide in the standard or samples. This is due to the 
competitive binding to resistin/visfatin antibody between biotinylated resistin/visfatin 
peptide and peptides in standard or samples. A standard curve of known concentration of 
resistin/visfatin peptide was established and the concentration of resistin/visfatin peptide 
in the samples was calculated accordingly. After the analysis, microplates were read by 
microplate reader capable of measuring the hormone level at 450 nm absorbance. 
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Statistical analysis  
 
Analysis of Variance (ANOVA) was performed on baseline variables (PASW 
Statistics version 22, 2013, SPSS Inc, Chicago, IL.) followed by Multivariate Analysis 
of Variance (MANOVA) with repeated measures were used to analyze the related data. 
Wilks’ Lamda time and group x time p-levels as well as MANOVA univariate ANOVA 
group effects were used to study the overall MANOVA effects. Within the MANOVA 
model, Greenhouse-Geisser univariate tests of within-subjects time and group x time 
effects and between-subjects univariate group effects were reported for each variable 
analyzed. ANOVA for repeated measures were used to calculate and analyze delta 
values or percent difference on selected variables to examine variations from baseline 
values. Delta values were calculated by subtracting the baseline values from the 12th 
week values. To calculate the percent change, previously calculated delta values were 
divided by T1 followed by multiplying by 100 [(T4-T1)/T1·100] when the probability of 
type I error was 0.05 or less then the data were considered statistically significant and 
statistical trends were considered when the probability error ranged between p > 0.05 to 
p < 0.10. All data are presented as means ± standard deviation for baseline to 12 wk data 
analyses. Finally, the relationship of changes in body composition to markers of 
inflammation were obtained by Pearson product correlation. 
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CHAPTER IV 
 
    RESULTS 
 
Figure 4.1 presents a Consort Diagram for participant recruitment, entry, and 
completion observed in this portion of the study. Twenty six (26) sedentary obese 
women participated in this portion of study. All 26 obese sedentary women (Age 
46.7±11.1 years, Body Fat 38.6±7.4, BMI 34.8±5.4 kg/m2) completed baseline testing 
and were cleared to participate in the study. Some of the participants dropped out of the 
study. The primary reasons for participants to drop out were due to time constraints, 
work, moving, falling sick, complaints about the exercise program (that it was too 
intense) and they did not want to participate in the control group once they found out 
they were in the control group.  
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Table 4.1 presents the participant demographics data. Twenty-Six obese women 
(age 46.7±11.1 years; weight 90.2±12.4 kg; BMI 34.8±5.4 kg/m2; Body fat 38.6±7.4; Fat 
free mass 45.3±6.5; REE 0.90±0.05; body fat % 45.8±4.2;) completed this portion of the 
12-week study (DE group n=12; C group n=14). One-way ANOVA no significant 
differences between groups in baseline age, weight, BMI, body fat, fat free mass, resting 
energy expenditure (REE) and percent body fat. 
 
Table 4.1 Baseline demographics for the exercise and diet-induced weight loss (DE) 
and control (C) groups 
 
 Exercise Group (N=12) 
 
 
 
 
Control Group (N=14)     P-value 
Age (years) 43.5±11.2 49.4±10.7                           0.18 
 
 
 
 
 
 
 
Weight (kg) 90.9±14.8 89.6±10.4                           0.80 
BMIa (kg/m²) 34.9±6.4 34.7±4.6                             0.92 
Body Fat (kg) 39.3±9.1 38.0±5.9                             0.68 
Fat Free Mass (kg) 45.3±5.6 45.4±7.5                             0.96 
REEb 0.90±0.04 0.90±0.06                           0.78 
Fat (%c) 
Waist/hip ratio 
46.1±3.4 
0.78±0.03 
45.7±4.9                             0.81 
0.79±0.06                            0.47 
 
 
 
VATd (kg) 
 
0.90±0.43 1.04±0.48 0.45 
Note: All data is presented as means ± SD at baseline. 
a Body mass Index 
b Resting Energy Expenditure 
c Dual Energy X-ray Absorptiometry 
d Visceral Adipose Tissue 
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Exercise and diet intervention effects 
 
 
 
Table 4.2 Changes in protein intake values obtained at 0 week (baseline) and 12 
weeks of program participation  
 
 
 
Group 0 weeks 12 weeks Group  p-value  
(GG) 
Total 
Calories 
(kcal) 
DE 
Control 
Time 
1696±395 
2142±748 
1936±641 
1431±280*† 
1793±508 
1626±450* 
1563±112 
1967±103† 
G=0.014 
T=0.037 
I=0.764 
Carbohydrate 
(gm) 
DE 
Control 
Time 
182.7±85.0 
236.6±107.4 
211.7±99.7 
119.6±28.6*† 
183.8±58.3 
154.2±56.5* 
151.1±16.4 
210.2±15.2† 
G=0.014 
T=0.009 
I=0.802 
Protein (gm) DE 
Control 
Time  
76.0±11.2 
85.8±31.6 
81.3±24.5 
84.1±21.4 
75.8±22.5 
79.7±22.0 
80.1±4.8 
80.8±4.5 
 
G=0.915 
T=0.886 
I=0.800 
Fat (gm) DE 
Control 
Time 
66.9±16.5 
82.4±31.3 
75.2±26.3 
60.2±19.9 
73.1±22.5 
67.2±21.9 
63.5±5.6 
77.7±5.2 
G=0.075 
T=0.144 
I=0.169 
Data are from 12 participants in the DE group and 14 participants in the C group (n=26) who completed the 12-week study. Data are 
presented for the Diet & Exercise Group (DE); Total calories; Carbohydrate;Protein and Fat.   Data are individual group (G) and time 
(T) data expressed as means ± SD, while group effects are presented as means ± SEM. MANOVA analysis revealed overall Wilks' 
Lambda time (p=0.089) and group x time (p=0.564) effects.  Univariate ANOVA p-levels from MANOVA analysis are presented for 
each variable.  Greenhouse-Geisser (GG) univariate ANOVA p-levels are listed for G, T and GxT interactions effects.  * indicates 
p<0.05 p-level significance from baseline.  † represents p<0.05 difference between groups. 
   
 
Table 4.2 represents the changes from baseline to 12-week between exercise and 
diet-induced weight loss and control group on total calories, carbohydrate, protein and 
fat intake in obese women. MANOVA analysis of all these above mentioned variables 
revealed overall time (Wilks’ Lamda p=0.089) and time by diet effects (Wilks’ Lamda 
p=0.564) which are not significant. Univariate ANOVA p-levels from MANOVA 
analysis are presented for each variable. Univariate analysis revealed significant time 
effects for total calories (p=0.037) and fat mass (p=0.009). Greenhouse-Geisser analysis 
showed significant time but not group x time interaction for total calories (T: p=0.037, I: 
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p=0.764) and carbohydrate intake (T: p=0.009, I: p=0.802). Greenhouse-Geisser analysis 
showed no significant time and group x time interaction for protein (T: p=0.886, I: 
p=0.800) and fat intake (T: p=0.144, I: p=0.169). 
Table 4.3 and figure 4.2 represent the changes from baseline to 12-week between 
exercise and diet-induced weight loss and control group on body composition and 
anthropometric measurements in obese women respectively. MANOVA analysis of 
body composition data revealed overall time (Wilks’ Lamda p=0.004) and time by diet 
effects (Wilks’ Lamda p<0.001). Univariate analysis revealed significant time effects for 
body weight (p<0.001), fat mass (p<0.001), and percent body fat (p=0.005). Univariate 
ANOVA p-levels from MANOVA analysis are presented for each variable. Greenhouse-
Geisser analysis showed significant time and group x time interaction for weight (T: 
p<0.001, I: p<0.001), fat mass (T: p=0.001, I: p<0.001), body fat percentage (T: 
p=0.005, I: p=0.002) and significant group x time interaction for visceral adipose tissue 
(T: p=0.041). Least significant difference post-hoc analysis revealed that participants in 
the DE group lost significantly more weight, fat mass, and body fat percent than the C 
group whose body composition values did not significantly change from baseline. Delta 
analysis from baseline values showed participants in the diet & exercise group lost more 
weight (DE: -5.9±4.0; C: 0.64±1.4 kg, p<0.001), fat mass (DE: -5.1±4.5; C: 0.4±1.5 kg, 
p=0.001) and body fat percentage (DE: -3.4±3.3; C: 0.18±1.9 kg, p=0.005). No 
differences between groups were observed changes in FFM (DE: -0.40±1.4; C: 0.13±2.0 
kg, p=0.695), changes in waist to hip ratio (DE: 0.001±0.02; C: 0.01±0.06 kg, p=0.570) 
and changes in visceral adipose tissue (DE: -180.7±203.5; C: -62.1±339.9 kg, p=0.302).  
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Based on these findings, hypothesis H1 indicating that there would be significant 
differences between the DE and C groups in body composition variables was accepted.   
The exercise and diet intervention promoted statistically significant differences in body 
composition measures compared to controls.  
The significant changes in body composition observed in response to the DE 
intervention leads us to further evaluate the effect of diet and exercise on blood markers 
such as glucose, triglyceride and insulin, inflammatory markers like IL-6 and TNF-α and 
adipose hormones such as leptin, visfatin and resistin and their correlations among each 
other to better understand their physiologic roles.  
Blood and inflammatory markers and hormone levels 
 
Table 4.4 Changes in blood markers, inflammatory markers and hormones values 
obtained at 0 week (baseline) and 12 weeks of program participation in obese women. 
MANOVA analysis of glucose and insulin revealed overall Wilks' Lambda time 
(p=0.149) and group x time (p=0.199) effects, IL-6 and TNF- α revealed overall Wilks' 
Lambda time (p=0.097) and group x time (p<0.001) effects and leptin, resistin and 
visfatin revealed overall Wilks' Lambda time (p=0.053) and group x time (p=0.028) 
effects. Univariate analysis revealed significant time effects for TNF- α (p=0.039) and 
tend to be significant for insulin (p=0.077), leptin (p=0.052), and visfatin (p=0.078). 
Univariate ANOVA p-levels from MANOVA analysis are presented for each 
variable.  Univariate ANOVA p-levels are listed by the Greenhouse-Geisser (GG)
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Table 4.3 Changes in anthropometric measures values obtained at 0 week (baseline) and 12 
weeks of program participation  
Variable Group 0 weeks 12 weeks Group p-value 
(GG) 
Weight (kg) DE 
Control 
Time 
90.9±14.8 
89.6±10.4 
90.2±12.4 
85.0±14.1*† 
90.2±10.7 
87.8±12.4* 
87.9±3.6 
89.9±3.3† 
G<0.001 
T<0.001 
I<0.001 
FM (kg) DE 
Control 
Time 
39.3±9.1 
38.0±5.9 
38.6±7.4 
34.1±8.8*† 
38.5±5.5 
36.5±7.4* 
36.7±2.1 
38.3±1.9† 
G<0.001 
T<0.001 
I<0.001 
FFM (kg) DE 
Control 
Time 
45.3±5.6 
45.4±7.5 
45.3±6.5 
44.9±5.8 
45.5±6.6 
45.2±6.14.90 
45.1±1.9 
45.5±17 
G=0.437 
T=0.695 
I=0.437 
BF (%) DE 
Control 
Time 
46.1±3.4 
45.7±4.9 
45.8±4.2 
42.7±5.0*† 
45.8±3.7 
44.4±4.6* 
45.8±0.8 
44.4±0.9† 
G=0.002 
T=0.005 
I=0.002 
W/H Ratio DE 
Control 
Time 
0.78±0.03 
0.79±0.06 
0.79±0.05 
0.78±0.03 
0.80±0.06 
0.79±0.05 
0.78±0.01 
0.80±0.01 
G=0.631 
T=0.570 
I=0.631 
VAT (kg) DE 
Control 
Time 
0.90±0.43 
1.04±0.48 
0.97±0.46 
0.72±0.32* 
0.98±0.30 
0.86±0.33 
0.81±0.11 
1.01±0.01 
G=0.293 
T=0.041 
I=0.302 
Data are from 12 participants in the DE group and 14 participants in the C group (n=26) who completed the 12-week study. 
Data are presented for the Diet & Exercise Group (DE); fat mass (FM) Fat Free Mass (FFM); percent body fat percentage 
(BF), and waist to hip (W/H) ratio.   Data are individual group (G) and time (T) data expressed as means ± SD, while group 
effects are presented as means ± SEM. MANOVA analysis revealed overall Wilks' Lambda time (p=0.004) and group x 
time (p<0.001) effects.  Univariate ANOVA p-levels from MANOVA analysis are presented for each variable.  
Greenhouse-Geisser (GG) univariate ANOVA p-levels are listed for G, T and GxT interactions effects.  * indicates p<0.05 
p-level significance from baseline.  † represents p<0.05 difference between groups. 
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Figure 4.2. Changes in body composition from baseline to 12-wk between exercise and diet-induced 
weight loss and control groups Data are presented as means ±SD of markers of fitness. *P<0.05 significant 
differences from baseline to 12-wk between the exercise and diet-induced weight loss and control groups 
on body composition. † represents p<0.05 difference between groups 
 
analysis to demonstrate the potential shape of the time or group x time interaction. 
Greenhouse-Geisser analysis showed significant time and group x time interaction for 
TNF- α (T: p=0.039, I: p==0.013), significant group x time interaction for IL-6 (I: p= 
0.001) and leptin (I: p=0.003) and tend to be significant time and group x time 
interaction for insulin (T: p=0.077, I: p==0.070), time for leptin (T: p=0.052) and time 
for visfatin (T; p=0.078). Figure 4.3, 4.4, 4.5, 4.6 & 4.7 represent changes from baseline 
to 12 –wk between our exercise and diet-induced weight loss and control group on 
leptin, IL-6, TNF-α resistin and visfatin.  
Figures 4.3 through 4.7 present changes in hormones evaluated for the DE and C 
groups.  Furthermore, participants in the diet & exercise group showed more decrease in 
glucose (DE: -3.8±19.8; C: -2.8±6.9 mg/dl, p=0.865), insulin (DE: -8.5±15.0; C: 
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0.12±7.7 IU/ml, p=0.070), IL-6 (DE: -1.9±4.2; C: 2.7±1.2 kg, p<0.001), TNF- α (DE: -
0.2±2.1; C: 1.7±1.5 kg, p<0.001) and leptin (DE: -19.8±21.9; C: 4.5±16.0 kg, p=0.003). 
Based on the MANOVA analysis, we can say that exercise and diet-induced weight loss 
has a significant effect on insulin, leptin, IL-6 and TNF-α during the period of 12 week 
intervention.  
H2 hypothesis stated exercise and diet intervention would promote statistical 
significant differences in resistin level compared to controls. Based on resistin (P=0.452) 
data observed, we therefore rejected our H2 hypothesis. We also hypothesized (H3) that 
exercise and diet intervention promoted significant differences in visfatin expression 
compared to the control. Based on our results, we found visfatin was not statistically 
significantly different (P=0.104) but they tended to differ. Therefore, we rejected our 
hypothesis H3.  
We also analyzed the relationship among the anthropometric measures, 
inflammatory and blood health markers at baseline and 12 week level. Table 4.4 and 4.5 
provide overview of correlations among different markers. We found a significant 
negative relationship between resistin and TNF-α (r=0.401: p=0.042) at baseline level 
and significant positive correlation between resistin with IL-6 (r=0.430: p=0.028) and 
visfatin (r=0.417: p=0.034) at 12 week level. We did not find any other significant 
correlation of resistin and visfatin with other anthropometric measures, inflammatory 
and blood health markers at baseline and 12 week level 
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Table 4.4 Changes in blood markers, inflammatory markers and hormones values obtained at 0 week 
(baseline) and 12 weeks of program participation 
Variable Group 0 week 12 weeks Group Mean p-value 
(GG) 
Glucose 
(mg/dl) 
DE 
Control 
Time 
99.6±21.5 
96.0±10.9 
97.7±16.4 
95.8±13.4 
93.2±9.2 
94.4±11.2 
97.7±3.5 
94.6±3.3 
G=0.865 
T=0.257 
I=0.865 
Insulin 
(IU/ml) 
DE 
Control 
Time 
27.3±45.7 
11.1±8.1 
18.6±31.9 
18.8±31.5 
11.2±5.4 
14.7±21.6 
23.1±7.6 
11.2±7.1 
G=0.070 
T=0.077 
I=0.07 
IL-6 
(ng/ml) 
DE 
Control 
Time 
7.2±1.5† 
3.4±1.3 
5.2±3.2 
5.3±1.7* 
6.2±1.5* 
5.8±1.6 
6.21±0.4 
4.81±0.4† 
G<0.001 
T=0.484 
I=0.001 
TNF-α 
(ng/ml) 
DE 
Control 
Time 
7.2±1.5† 
5.6±1.6 
6.3±1.8 
7.0±1.4 
7.3±.6 
7.2±1.0 
7.07±0.3 
6.43±0.3 
G<0.001 
T=0.039 
I=0.013 
Leptin 
(ng/ml) 
DE 
Control 
Time 
56.2±26.9 
54.0±19.5 
55.0±22.8 
36.4±23.1* 
58.5±28.9 
48.3±28.2† 
46.3±6.6 
56.2±6.1† 
G=0.003 
T=0.052 
I=0.003 
Resistin 
(ng/ml) 
DE 
Control 
Time 
223.8±108.2 
233.3±136.2 
228.9±121.8 
242.4±127 
293.1±178.4 
269.7±156 
233.1±35.7 
263.2±33.1 
G=0.452 
T=0.159 
I=0.452 
Visfatin 
(ng/ml) 
DE 
Control 
Time 
24.1±13.2 
46.2±51.1 
36.0±39.5 
25.0±11.4 
66.4±82.1 
47.3±63.3 
24.5±14.1 
56.3±13.1 
G=0.104 
T=0.078 
I=0.104 
Data are from 12 participants in the DE group and 14 participants in the C group (n=26) who completed the 12-week study. Data are presented for the Diet & 
Exercise Group (DE); Interleukin-6 (IL-6) and Tumor Necrosis Factor- Alpha (TNF- α). Data are individual group (G) and time (T) data expressed as means ± 
SD, while group effects are presented as means ± SEM. MANOVA analysis of glucose and insulin revealed overall Wilks' Lambda time (p=0.149) and group x 
time (p=0.199) effects, IL-6 and TNF- α revealed overall Wilks' Lambda time (p=0.097) and group x time (p<0.001) effects and leptin, resistin and visfatin 
revealed overall Wilks' Lambda time (p=0.053) and group x time (p=0.028) effects.  Univariate ANOVA p-levels from MANOVA analysis are presented for each 
variable.  Greenhouse-Geisser (GG) univariate ANOVA p-levels are listed for G, T and GxT interactions effects.  * indicates p<0.05 p-level significance from 
baseline. † represents p<0.05 difference between groups. 
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Figure 4.3. Changes in leptin from baseline to 12-wk between exercise and diet-induced weight loss and 
control groups Data are presented as means ±SD of markers of fitness. *P<0.05 significant differences from 
baseline to 12-wk between the exercise and diet-induced weight loss and control groups on leptin. † 
represents p<0.05 difference between groups. 
 
 
 
Figure 4.4. Changes in IL-6 from baseline to 12-wk between exercise and diet-induced weight loss and 
control groups Data are presented as means ±SD of markers of fitness. *P<0.05 significant differences from 
baseline to 12-wk between the exercise and diet-induced weight loss and control groups on IL-6. † represents 
p<0.05 difference between groups. 
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Figure 4.5. Changes in TNF-α from baseline to 12-wk between exercise and diet-induced weight loss and 
control groups Data are presented as means ±SD of markers of fitness. *P<0.05 significant differences from 
baseline to 12-wk between the exercise and diet-induced weight loss and control groups on TNF-α. † 
represents p<0.05 difference between groups. 
.  
 
Figure 4.6. Changes in resistin from baseline to 12-wk between exercise and diet-induced weight loss and 
control groups Data are presented as means ±SD of markers of fitness. *P<0.05 significant differences from 
baseline to 12-wk between the exercise and diet-induced weight loss and control groups on resistin. † 
represents p<0.05 difference between groups. 
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Figure 4.7. Changes in visfatin from baseline to 12-wk between exercise and diet-induced weight loss and 
control groups Data are presented as means ±SD of markers of fitness. *P<0.05 significant differences from 
baseline to 12-wk between the exercise and diet-induced weight loss and control groups on visfatin. † 
represents p<0.05 difference between groups.  
  
Furthermore, we analyzed the relationship among changes in anthropometric 
measures, blood health markers, inflammatory markers and adipose hormones level.  
Table 4.6 provides overview of correlations among different inflammatory markers. We 
found significant positive correlations between ∆ weight and ∆ fat (r= 0.919, p<0.001), 
∆ weight and ∆ triglyceride (r= 0.397, p=0.045), ∆ weight and ∆ insulin (r= 0.397, 
p=0.045), ∆ weight and ∆ leptin (r= 0.785, p<0.001), ∆ fat and ∆ leptin (r= 0.681, 
p<0.001), ∆ FFM and ∆ insulin (r=0.501, p=0.009), ∆ REE and ∆ Waist/hip ratio 
(r=0.391, p=0.049), ∆ REE and ∆ FFM (r= 0.624, p=0.001), ∆ triglyceride and ∆ leptin 
(r=0.421, p=0.032), ∆ insulin and ∆ leptin (r=0.425, p=0.03), ∆ IL-6 and ∆ resistin 
(r=0.430, p=0.028), ∆ resistin and ∆ visfatin (r=0.417, p=0.034). 
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Table 4.5 Overview of correlations among different inflammatory markers at baseline level  
 
 
 
 
 Weight  Fat FFM Waist/hip ratio REE  VAT Carbohydrate Fat Protein Triglyceride Glucose Insulin IL-6 TNF- α Leptin Resistin Visfatin 
Weight   0.870  
p<0.001 
0.829  
p<0.001 
0.343 
p=0.086 
-0.020 
p=0.924 
0.636 
P<0.001 
-0.128 
p=0.535 
-0.168 
p=0.413 
0.001 
p=0.997 
0.019 
p=0.928 
0.235  
p=0.247 
0.178 
p=0.385 
0.007 
p=0.973 
-0.174 
p=0.395 
0.640 
p<0.001 
0.072 
p=0.726 
-0.341 
p=0.088 
Fat    0.449 
p=0.021 
0.068 
p=0.741 
-0.120 
p=0.558 
0.734 
p<0.001 
 
-0.062 
p=0.763 
-0.051 
p=0.804 
0.061 
p=0.768 
0.-0.183 
p=0.372 
0.269 
p=0.185 
0.094 
p=0.648 
0.003 
p=0.989 
-0.299 
p=0.138 
0.718 
p<0.001 
0.058 
p=0.777 
-0.341 
p=0.088 
FFM      0.550 
p=0.004 
0.100 
p=0.628 
0.348 
p=0.081 
-0.139 
p=0.497 
 
-0.241 
p=0.235 
-0.080 
p=0.699 
0.256 
p=0.206 
0.144 
p=0.484 
0.200 
p=0.328 
-0.003 
p=0.988 
0.018 
p=0.932 
0.345 
p=0.084 
0.064 
p=0.757 
-0.236 
p=0.246 
Waist/hip 
ratio 
     0.069 
p=0.737 
0.209 
p=0.305 
0.091 
p=0.091 
-0.164 
p=0.424 
-0.075 
p=0.718 
0.265 
p=0.191 
0.147 
p=0.473 
-0.021 
p=0.918 
0.061 
p=0.767 
0.206 
p=0.313 
0.068 
p=0.742 
-0.138 
p=0.501 
-0.265 
p=0.191 
REE       -0.098 
p=0.634 
0.014 
p=0.944 
0.041 
p=0.844 
-0.189 
p=0.354 
0.139 
p=0.500 
0.269 
p=0.184 
0.238 
p=0.242 
-0.024 
p=0.906 
0.347 
p=0.082 
0.183 
p=0.370 
0.016 
p=0.938 
0.137 
p=0.505 
VAT        0.062 
p=0.765 
-0.121 
p=0.556 
-0.257 
p=0.205 
0.035 
p=0.865 
0.311 
p=0.122 
0.143 
p=0.485 
-0.162 
p=0.428 
-0.209 
p=0.306 
0.507 
p=0.008 
-0.086 
p=0.675 
-0.213 
p=0.296 
Carbohydrate        -0.062 
p=0.763 
0.493 
p=0.011 
-0.129 
p=0.531 
-0.031 
p=0.882 
-0.017 
p=0.936 
-0.075 
p=0.716 
-0.374 
p=0.060 
-0.066 
P=0.748 
0.472 
p=0.015 
-0.085 
p=0.679 
Fat          0.340 
p=0.089 
-0.146 
p=0.475 
0.354 
p=0.076 
-0.028 
p=0.892 
-0.080 
p=0.696 
-0.484 
p=0.012 
0.087 
p=0.673 
0.272 
p=0.179 
-0.100 
p=0.626 
Protein           -0.314 
p=0.118 
-0.041 
p=0.843 
-0.004 
p=0.986 
-0.139 
p=0.500 
-0.451 
p=0.021 
-0.011 
p=0.956 
0.365 
p=0.067 
0.010 
p=0.962 
 
Triglyceride 
           0.269 
p=0.184 
-0.095 
p=0.644 
-0.139 
p=0.497 
0.156 
p=0.445 
0.093 
p=0.650 
-0.371 
p=0.062 
0.184 
p=0.368 
 
Glucose 
            0.302 
p=0.133 
0.036 
p=0.863 
-0.041 
p=0.842 
0.237 
p=0.243 
-0.365 
p=0.067 
-0.113 
p=0.582 
 
Insulin 
             0.050 
p=0.808 
0.086 
p=0.676 
0.111 
p=0.590 
0.093 
p=0.652 
-0.080 
p=0.699 
 
IL-6 
              0.234 
p=0.249 
-0.207 
p=0.310 
0.195 
p=0.340 
-0.352 
P=0.078 
 
TNF-α 
               -0.042 
p=0.840 
-0.401 
P=0.042 
0.082 
P=0.690 
 
Leptin 
                0.102 
p=0.621 
-0.168 
p=0.412 
 
Resistin 
                 
 
 
-0.156 
p=0.447 
Visfatin                   
 p<0.05 
 p>0.05 – p<0.10 
*P<0.05 significant correlation. 
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Table 4.6 Overview of correlations among different inflammatory markers at 12 week level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7 Overview of correlations among different inflammatory markers  
 Weight Fat FFM 
Waist/hip 
ration REE  VAT 
 
Carbohydrat
e 
 
Fat Protein Triglyceride Glucose Insulin IL-6 TNF- α Leptin Resistin Visfatin 
Weight  0.919  
P<0.001 
0.288  
p=0.153 
0.106 
p=0.607 
0.137 
p=0.504 
0.792 
p<0.001 
0.122 
p=0.554 
0.256 
p=0.207 
0.273 
p=0.178 
0.397 
p=0.045 
-0.108  
p=0.601 
0.397 
p=0.045 
0.284 
p=0.160 
0.401 
p=0.042 
0.785 
p<0.001 
0.054 
p=0.793 
0.327 
p=0.103 
Fat   -0.077 
p=0.708 
0.016 
p=0.938 
-0.084 
p=0.682 
0.760 
p<0.001 
0.234 
p=0.251 
0.300 
p=0.137 
0.760 
p<0.001 
0.194 
p=0.342 
-0.152 
p=0.459 
0.181 
p=0.375 
0.295 
p=0.143 
0.344 
p=0.085 
0.681 
p<0.001 
0.112 
p=0.587 
0.348 
p=0.081 
 
FFM  
   0.310 
p=0.123 
0.624 
p=0.001 
0.627 
p<0.001 
-0.060 
p=0.771 
0.144 
p=0.482 
0.410 
p=0.037 
0.509 
p=0.008 
0.112 
p=0.586 
0.501 
p=0.009 
-0.084 
p=0.685 
0.238 
p=0.241 
0.332 
p=0.098 
-0.121 
p=0.555 
-0.026 
p=0.900 
 
Waist/hip 
ratio 
    0.391 
p=0.049 
0.482 
P=0.013 
-0.109 
p=0.596 
-0.166 
p=0.418 
-0.189 
p=0.356 
0.056 
p=0.786 
0.075 
p=0.717 
0.111 
p=0.590 
-0.044 
p=0.830 
0.219 
p=0.282 
0.377 
p=0.058 
-0.051 
p=0.806 
0.125 
p=0.542 
 
REE 
     0.414 
p=0.035 
0.408 
p=0.039 
0.312 
p=0.121 
-0.163 
p=0.426 
0.245 
p=0.228 
-0.002 
p=0.993 
0.446 
p=0.022 
-0.064 
p=0.755 
0.312 
p=0.121 
0.218 
p=0.285 
-0.188 
p=0.357 
0.108 
p=0.412 
 
VAT 
      0.282 
p=0.162 
0.205 
p=0.316 
0.162 
p=0.428 
0.458 
p=0.019 
0.175 
p=0.392 
0.002 
p=0.992 
-0.275 
p=0.173 
0.018 
p=0.931 
0.452 
P=0.020 
-0.165 
p=0.420 
0.018 
p=0.931 
Carbohydrate        0.597 
p<0.001 
0.004 
p=0.986 
0.151 
p=0.462 
-0.045 
p=0.827 
-0.112 
p=0.585 
0.100 
p=0.628 
0.168 
p=0.412 
0.360 
p=0.070 
0.296 
p=0.142 
0.078 
p=0.704 
Fat         0.497 
p=0.010 
0.169 
p=0.410 
0.081 
p=0.694 
-0.116 
p=0.574 
-0.130 
p=0.527 
-0.246 
p=0.227 
0.271 
p=0.181 
0.126 
p=0.538 
0.175 
p=0.393 
 
Protein 
         0.324 
p=0.106 
0.305 
p=0.129 
-0.118 
p=0.565 
-0.297 
p=0.141 
-0.413 
p=0.036 
-0.126 
p=0.540 
-0.254 
p=0.210 
-0.123 
p=0.548 
 
Triglyceride 
          0.043 
p=0.833 
0.205 
p=0.314 
-0.043 
p=0.835 
0.275 
p=0.174 
0.421 
p=0.032 
-0.058 
p=0.779 
0.212 
p=0.298 
 
Glucose 
           0.122 
p=0.552 
0.073 
p=0.724 
0.174 
p=0.395 
-0.073 
p=0.723 
0.057 
p=0.782 
0.072 
p=0.727 
 
Insulin 
            0.174 
p=0.395 
0.183 
p=0.370 
0.425 
p=0.030 
0.137 
p=0.505 
0.044 
p=0.832 
 
IL-6 
             0.270 
p=0.183 
0.019 
p=0.927 
0.430 
p=0.028 
0.351 
P=0.078 
 
TNF-α 
              0.341 
p=0.089 
0.064 
P=0.756 
0.203 
P=0.319 
 
Leptin 
               0.064 
p=0.755 
0.342 
p=0.087 
 
Resistin 
                
 
 
0.417 
p=0.034 
Visfatin                  
     p<0.05 
      p>0.05 – p<0.10 
*P<0.05 significant correlation. 
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Table 4.7 Overview of correlations among different inflammatory markers  
 ∆ Weight ∆ Fat ∆ FFM ∆  Waist/hip 
ratio 
∆ REE  ∆ VAT ∆ Protein ∆ 
Carbohydrate 
∆ Fat ∆ Triglyceride ∆ Glucose ∆ Insulin ∆ IL-6 ∆ TNF- α ∆ Leptin ∆ Resistin ∆ Visfatin 
 
∆ Weight 
  0.919  
p<0.001 
0.288  
p=0.153 
0.106 
p=0.607 
  0.137           0.368               -0.252 
p=0.504       p=0.064          p=0.215 
0.206 
p=0.312 
0.019 
p=0.926 
0.397 
p=0.045 
-0.108  
p=0.601 
0.397 
p=0.045 
0.284 
p=0.160 
0.401 
p=0.042 
0.785 
p<0.001 
0.054 
p=0.793 
0.327 
p=0.103 
 
∆ Fat 
   -0.077 
p=0.708 
0.016 
p=0.938 
  -0.084          0.427              -0.200 
p=0.682      p=0.029          p=0.327 
0.154 
p=0.453 
0.052 
p=0.801 
0.194 
p=0.342 
-0.152 
p=0.459 
0.181 
p=0.375 
0.295 
p=0.143 
0.344 
p=0.085 
0.681 
p<0.001 
0.112 
p=0.587 
0.348 
p=0.081 
 
∆ FFM  
    0.310 
p=0.123 
  0.624           -0.203            -0.185 
p<0.001       p=0.321         p=0.367 
0.181 
p=0.376 
-0.016 
p=0.937 
0.509 
p=0.008 
0.112 
p=0.586 
0.501 
p=0.009 
-0.084 
p=0.685 
0.238 
p=0.241 
0.332 
p=0.098 
-0.121 
p=0.555 
-0.026 
p=0.900 
 
∆  Waist/hip 
ratio 
       0.391            -0.519            -0.094 
p=0.049       p=0.007         p=0.647 
-0.124 
p=0.547 
-0.190 
p=0.353 
0.056 
p=0.786 
0.075 
p=0.717 
0.111 
p=0.590 
-0.044 
p=0.830 
0.219 
p=0.282 
0.377 
p=0.058 
-0.051 
p=806 
0.125 
p=0.542 
 
∆ REE 
                            -0.167           -0.105 
                     p=0.413        p=0.610 
-0.017 
p=0.933 
-0.114 
p=0.580 
0.245 
p=0.228 
-0.002 
p=0.993 
0.446 
p=0.022 
-0.064 
p=0.755 
0.312 
p=0.121 
0.218 
p=0.285 
-0.188 
p=0.357 
0.108 
p=0.412 
∆VAT                                                  -0.159 
                                         p=0.439 
0.203 
p=0.320 
-0.059 
p=0.776 
0.014 
p=0.946 
-0.095 
p=0.644 
0.143 
p=0.487 
0.101 
p=0.622 
-0.007 
p=0.974 
0.091 
p=0.657 
0.136 
p=0.508 
0.200 
p=0.328 
∆ Protein         0.471 
p=0.015 
0.513 
p=0.007 
-0.220 
p=0.280 
-0.026 
p=0.902 
-0.074 
p=0.719 
-0.175 
p=0.392 
-0.527 
p=0.006 
-0.373 
p=0.061 
-0.157 
p=0.444 
-0.326 
p=0.104 
∆ Carbohydrate          0.519 
p=0.007 
0.052 
p=0.800 
-0.084 
p=0.683 
0.113 
p=0.582 
0.121 
p=0.557 
-0.201 
p=0.326 
-0.139 
p=0.500 
0.129 
p=0.530 
-0.034 
p=0.868 
∆ Fat           -0.050 
p=0.809 
0.176 
p=0.388 
-0.025 
p=0.902 
-0.105 
p=0.609 
-0.205 
p=0.315 
-0.244 
p=0.229 
0.010 
p=0.960 
0.223 
p=0.274 
 
∆  Triglyceride 
           0.043 
p=0.833 
0.205 
p=0.314 
-0.043 
p=0.835 
0.275 
p=0.174 
0.421 
p=0.032 
-0.058 
p=0.779 
0.212 
p=0.298 
 
∆  Glucose 
            0.122 
p=0.552 
0.073 
p=0.724 
0.174 
p=0.395 
-0.073 
p=0.723 
0.057 
p=0.782 
0.072 
p=0.727 
 
∆  Insulin 
             0.174 
p=0.395 
0.183 
p=0.370 
0.425 
p=0.030 
0.137 
p=0.505 
0.044 
p=0.832 
 
∆  IL-6 
              0.270 
p=0.183 
0.019 
p=0.927 
0.430 
p=0.028 
 
0.351 
P=0.078 
 
∆  TNF-α 
               0.341 
p=0.089 
0.064 
P=0.756 
0.203 
P=0.319 
 
∆  Leptin 
                0.064 
p=0.755 
0.342 
p=0.087 
 
∆  Resistin 
 
                 
 
 
0.417 
p=0.034 
∆ Visfatin 
 
                  
   p<0.05;    p>0.05 – p<0.10 
∆ = Post value (12 weeks) - Pre value (0 weeks). *P<0.05 significant correlation. 
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We hypothesized (H4) that there will be significant correlation between ∆ resistin 
and ∆ visfatin. Based on our result, r=-0.417. p=0.034, we accepted our hypothesis H4 
but we did not find any significant correlation between ∆ resistin and ∆ leptin so we 
rejected hypothesis H5, r=-0.064, p=0.755. Figure 8 shows correlation data between ∆ 
resistin and ∆ visfatin. We found that ∆ visfatin were tended to correlate to ∆ leptin but 
not statistically significant, r=0.342, p=0.087. Therefore, we rejected our hypothesis H6.  
 
Figure 4.8. Significant correlation data between ∆ resistin and ∆ visfatin. 
 
We did not find statistically significant correlation between ∆ resistin and ∆ 
TNF-α r=-0.064, p=0.756. So, we rejected hypothesis H7. Correlation data revealed that 
∆ visfatin and ∆ TNF-α (r=0.351; p=0.078), ∆ visfatin and ∆ triglyceride (r=0.212; 
p=0.298) and ∆ visfatin and ∆ waist/hip ratio were not correlated. Hence, we rejected 
hypotheses H8, H9 and H10 respectively.  We also did not find significant correlation 
between ∆ resistin and ∆ waist/hip ratio (r=-0.051; p=0.806), ∆ resistin and ∆ 
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triglyceride (r=-0.058; p=0.779) and ∆ resistin and ∆ REE (r=-0.188; p=0.357). 
Therefore, we rejected the hypotheses H11, H12 and H13 respectively.  
We also looked at the correlations between ∆ visfatin and ∆ REE (r=-0.168; 
p=0.412), could not find any significant correlation so we rejected hypothesis H14. We 
found a strong positive significant correlation between ∆ resistin and ∆ IL-6 (r=0.430; 
p=0.028). Hence, we accepted hypothesis H15. Figure 9 shows correlation data between 
∆ resistin and ∆ IL-6.  
 
Figure 4.9. Significant correlation data between ∆ IL-6 and ∆ resistin. 
 
Finally, we could not find significant correlation between ∆ visfatin and ∆ IL-6 
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between groups in leptin, IL-6 and TNF-α while visfatin and insulin tended to differ and 
no significant differences between groups in resistin and glucose. However, significant 
positive correlations were seen between changes in resistin with changes in IL-6 and 
changes in visfatin. These findings indicate that exercise and diet-induced weight loss 
has an effect on resistin and visfatin. We also looked at the correlation between visceral 
adipose tissue with anthropometric measures, inflammatory and other blood health 
markers at baseline, 12 week and changes between post and pre values. We found 
significant positive correlation between visceral adipose tissue with weight(r=0.636: 
p<0.001), fat (r=0.734: p<0.001) and leptin (r=0.507: p=0.008) at baseline level and 
significant positive correlation with weight (r=0.792: p<0.001), fat (r=0.760: p<0.001), 
fat free mass (r=0.627: p<0.001), waist/hip ratio (r=0.482: p=0.013), REE (r=0.414: 
p=0.035), triglyceride (r=0.458: r=0.019) and leptin (r=0.452: p=0.020) at 12 week of 
intervention. We also found significant positive correlation between changes in visceral 
adipose tissue with changes in fat (r=0.427: p=0.029) and significant negative 
correlation between changes in waist/hip ratio (r=-0.519: p=0.007) after 12 week of 
exercise and dietary intervention.  
Furthermore, we looked at the correlation between changes in protein intake with 
changes in anthropometric measures, inflammatory and other blood health markers 
between the groups. We found significant negative correlation between protein intake 
and TNF-α (r=-0.451: p=0.021) at baseline level and positive correlation between 
protein intake with fat (r=0.760: p<0.001), fat free mass (r=0.410: p=0.037) and 
negatively correlated with TNF-α (r=-0.413: p=0.036). Consequently, we also found 
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significant negative correlation between changes in protein intake with changes in TNF-
α (r=-0.527: p=0.006). We did not find significant correlation between changes in 
protein intake with changes in visaftin (r=-0.326, p=0.104) and changes in resistin (r=-
0.157, p=0.444. 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
Obesity has been a major public health crisis from the last few decades due to 
mainly inexpensive food supplies and sedentary jobs [191]. Previous studies [2, 4, 5] 
have shown an association between central and total obesity with different inflammatory 
markers, but this association has not been fully comprehended. Obesity is a chronic low 
grade inflammation and associated with increase in inflammatory markers [16, 43, 45, 
47, 127].  Correlating different inflammatory markers with each other, separately in men 
and women will help in understanding the basic mechanism or association between 
obesity and inflammation.  
This is the first study that shows the effect of exercise and diet-induced weight 
loss on levels of resistin and visfatin and their correlations with other health, blood and 
inflammatory markers. In this study, twenty-six obese women were assigned to an 
exercise and diet group or a non-exercise and non-diet control group. No significant 
differences were observed between groups in baseline age, weight, BMI, or percent body 
fat as determined by ANOVA. Results revealed that participants in the exercise and diet 
intervention group experienced significant reductions in body weight and fat mass with 
no changes observed in fat free mass (FFM) in comparison to controls. Participants also 
improved their fitness, some markers of health, and experienced a significant reduction 
in some markers of inflammation. Our investigation extended previous research by 
examining the effects of exercise and diet-induced weight loss on resistin and visfatin 
and their correlation with anthropometric markers, blood health markers and other 
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inflammatory markers [126, 137, 138, 181, 185]. We found that exercise and diet-
induced weight loss resulted in an overall effect on these markers with more influence 
on some markers than others. We found that diet and exercise group had significant 
weight loss but no significant change in resistin level. Resistin was also not correlated 
with weight (r=0.054, p=0.793), fat free mass (r=0.112, p=0.587) or visceral adipose 
tissue (r=0.136, p=0.508). 
Previous studies [27, 140, 151, 168, 185] showed mixed results on effects of 
exercise and/or hypocaloric diet on resistin. For example, Reinehr and colleagues [140] 
studied the change in weight status and resistin level over a period of 1 year. 38 obese 
children had 1-year outpatient Obeldick’s intervention program which was based on 
physical exercise, nutrition education (high carbohydrate, fat reduced diet), and behavior 
therapy including individual psychological care of the child and his or her family.  They 
found significant weight change (p<0.001) but no significant change in resistin levels 
(p=0.079). Koebnick et al [138] also showed similar results on 50 overweight to obese 
individuals who underwent dietary and physical activity intervention as compared to 
controls (n=20). Nutritional consulting was provided for a time period of 16 weeks, 
weekly during the first 8 weeks and biweekly for another 8 weeks. Participants were 
instructed to increase physical activity level during their daily routine (taking stairs 
instead of escalators, standing during a telephone call instead of sitting). Walking, light 
jogging, and gymnastics were suggested as programmed sports activities. They had a 
mean weight reduction of 4.5 kg and significant increase in serum resistin level (3.6±0.2 
vs 4.3±0.2, p<0.001). The increase in serum resistin level observed in this study 
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contradicted the physiological understanding of resistin action, where a strong 
relationship among adiposity, insulin resistance and resistin was observed.  
Bai et al [177] reported the influence of exercise prescription on plasma resistin 
for overweight and obese students. In this study, participants exercised aerobically at an 
intensity of 60%-70% of functional capacity for a session of 60 mins each time, 5 times 
per week and 13-15 levels of rate of perceived exertion. Energy metabolism was 500-
600 kcal at a time. The relative indexes were detected after 8 weeks. Their results 
showed that there was a significant decrease in weight, BMI, percentage body fat and 
blood sugar (P<0.01). Plasma resistin was significantly different in male students 
(P<0.01), however the female students were significantly different (P<0.05). Resistin 
also had significant correlation with BMI in male students but not in female students. 
Vendrell et al [129] found that among a surgically treated morbidly obese group, body 
weight decreased significantly and weight loss was best predicted by resistin 
concentration after weight loss. They found resistin was significantly positively 
correlated with weight (r=0.48, p<0.001) and fat-free mass (r=0.39, p<0.01). Their 
results do not agree with the results obtained during our exercise and diet-induced 
weight loss study.  
We also did not find any significant correlation between change in resistin with 
change in insulin (r= 0.137, p=0.505). There are conflicting evidence existed about the 
association of resistin with insulin resistance, because several studies reported no 
association of resistin with insulin resistance or indicators of type-2 diabetes mellitus 
[192-194]. There was a study conducted by Mozillo et al [136] studying the effect of 
 84 
 
weight loss in response of lifestyle modification program on adipose tissue derived 
cytokines in obese individual with insulin resistance. They found that participants had a 
6.9 ± 0.1 kg average weight loss, with a significant improvement in insulin sensitivity 
index. They did not find any change in resistin levels in response to the intervention 
which was comparable with our results.  
 In our investigation, we found that IL-6 (7.2±1. vs 5.3±1.75, p= 0.484) and TNF-
α (7.2±1.5 vs 7.0±1.4, p=0.039) tended to reduce through the exercise program in diet and 
exercise group as compared to control group. Similar results were also reported by 
Lambert and colleagues [195]. They conducted a study on obese elderly persons, 
evaluated 12 wk of exercise (aerobic and resistance) or 12 wk of weight loss (∼7% 
reduction) effect. Participants in the exercise group participated in exercise-training 
sessions (3 days/wk) followed by a physical therapist. The exercise program consisted of 
physical therapy, endurance, and resistance exercise. Each session lasted around 90 min 
included 15 min of flexibility exercises, 20–30 min of aerobic exercise, 30–40 min of 
progressive resistance training (PRT), and 15 min of balance exercises. Participants in 
the weight loss group received a combination of an energy-deficit diet and behavior 
therapy. They had a balanced diet to provide an energy deficit of 500–750 kcal/day with 
a goal of 1–2% loss of body weight per week. Participants lost significant weight in 
weight loss group (−7.5 ± 1.2 kg, p = 0.001) as compared to exercise group (−0.3 ± 0.8 
kg, P = 0.74). They found significant 50% decrease in IL-6 and TNF-α (P<0.05). Geilen 
et al [196] also conducted a study on 20 male congestive heart stable patients, 
randomized to a training group (n=10) or a control group (n=10). Training group had 
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aerobic exercise at about 70% VO2max for 20 min/d for 60 min/wk. Participants in 
training group showed a significant 42% reduction in IL-6 level. However, they did not 
find any significant change in level of resistin (p=0.159) across the group during an 
intervention period.  
We also found a statistically significant positive correlation between changes in 
resistin and changes in IL-6 (r=0.430, p=0.028). Interestingly, a study conducted by 
Kaser et al [103] showed that human peripheral blood mononuclear cells seem to be a 
major source of resistin and is strongly increased 2.5-fold by the proinflammatory 
cytokines interleukin-6 (IL-6). They also showed that in human resistin may be a link in 
the well-known association between inflammation and insulin resistance. Another study 
conducted by Tuttolomondo et al [197] showed that higher plasma levels of IL-6 and 
resistin in diabetic subjects with foot ulcers. Subjects having diabetes with foot ulcers 
(n=34) and diabetes without foot ulcers (n=37) were recruited. They found subjects 
having diabetes with foot ulcer have higher median plasma levels of IL-6 [3.21 (1.23-
5.34) pg/ml vs 2.73 (1.24-3.97 pg/ml)] and resistin [3.860 (2.96-6.29 ng/ml) vs 3.690 
(2.37-6.5 ng/ml)]. Stejskal et al [198] conducted a study on patients with type 2 diabetes 
mellitus and patients with acute inflammatory disease. They divided patients into 3 
groups: group A - with clinical signs of inflammatory disease of respiratory tract (n=35); 
group B - with well controlled type 2 DM treated by oral antidiabetic drugs, without 
clinical signs of inflammation and negative case history of acute disease (n=12); group C 
- without clinical signs of inflammation and negative case history of acute disease 
(n=77). They showed patients with clinical signs of severe inflammation had higher 
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concentrations of IL-6 and resistin. They also showed significant positive correlation 
between resistin and inflammatory markers (correlation coefficient 0.3-0.5). All the 
above mentioned studies agreed with our finding of a significant positive correlation 
between changes in resistin and changes in IL-6. 
Based on the results of past research studies, we could say that circulating 
resistin level increased in obese people in correlation with inflammatory markers 
especially IL-6 and TNF-α. Increase in serum resistin was observed in obese people as 
compared to their lean counterparts. On the contrary, our study reported that exercise 
and diet-induced weight loss led to the reduction in IL-6 level but at the same time 
increased resistin level which normally as a pro-inflammatory marker, led to an increase 
in IL-6. Therefore, the decrease in inflammatory markers such as IL-6 seen in weight 
loss was masked by an increase in resistin level in our study. Another reason of this 
contradiction could be due to the degree of severity of the baseline inflammatory burden 
or some other inflammatory markers that could have influenced the level of resistin. We 
also showed a significant positive correlation between changes in resistin and changes in 
IL-6 which indicated that there were some other pro-inflammatory or inflammatory 
factors affecting the level of resistin. Further research is warranted to explore other 
factors, inflammatory or adipose cytokines, which affect the level of resistin in 
overweight or obese people. 
In our study, we found that exercise and diet-induced weight loss led to slight 
increase in mean visfatin level in exercise group as compared to control group but it was 
not statistically significant (DE: 0.85±15.0; C: 20.2±37.1 ng/ml, p=0.078). Our result 
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was contradicted to the result reported by Seo et al [199] on obese middle-aged women 
for 12 weeks of combined resistance and aerobic exercise training program. They 
reported significant change in body composition and reduction in visfatin levels. Brema 
et al [200] also showed significant reduction in visfatin level (~80%) after 12 weeks of 
aerobic exercise training in severely obese young subjects with type 2 diabetes. Another 
study conducted by De Luis et al [142] on 41 morbidly obese patients, provided 
hypocaloric diet with mean caloric intake of 1741.9±812.7 kcal/day (49% of 
carbohydrates, 28% of lipid and 23% of proteins) for two months. Results have shown 
that there was weight loss of average 4.41% in morbidly obese patients leading to 
decrease in BMI, weight, fat mass, fat free mass, waist circumference, systolic blood 
pressure, serum glucose, total cholesterol, insulin and HOMA. However, no significant 
decrease in visfatin concentration (43.5+30.8 vs. 47.1+38.1 ng/ml) was seen which were 
consistent with our results. Another group of researchers [157] conducted a dietary 
intervention on 47 pre-menopausal women (age 38·7 ± 1·7 years, range 25–57 years, 
BMI 27·9 ± 1·4 kg/m2, range 17·3–50·5 kg/m2). The diet was designed to provide 25–
30% of kcals from fat, 55–60% of kcals from carbohydrates, and 10–15% of kcals from 
proteins. Overall, participants had 600 kcal/day less than the individually calculated 
energy requirements. Results showed that dietary intervention led to decrease in body 
weight and BMI by 8%, body fat mass by 16% and waist circumference by 9% in the 
entire group of overweight/obese women. Twelve week hypocaloric weight reducing 
diet caused an increase of visfatin mRNA levels (P < 0·05) and tended to decrease 
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visfatin plasma levels in the entire overweight/obese group (P < 0·1). Their results also 
agreed with our findings.  
We also found positive correlations between changes in visfatin and changes in 
resistin (r=0.417; p=0.034) but there were no significant correlations between changes in 
visfatin with changes in weight (r=0.327; p=0.103), changes in fat mass (r=0.348; 
p=0.081), or changes in FFM (r= -0.026; p=0.900). A study conducted by Berndt et al 
[123] showed that visfatin plasma concentration correlates positively with the BMI (r = 
0.250; p = 0.004), percent body fat (r = 0.220; p = 0.01), and negatively with 
subcutaneous visfatin mRNA expression (r = -0.424; p< 0.0001) which contradicted our 
results. Interestingly, Novak and colleagues [201] showed negative correlation between 
visfatin and waist circumference (p=0.027). The same conclusion was also drawn by 
Botella-Carretero et al [15]. They also showed increase in serum visfatin level after 
bariatric surgery in relation to the amount of weight lost and to the changes in waist 
circumference, and this increase was higher in diabetic patients.  
Furthermore, we did not find any significant correlation between changes in 
protein intake with changes in resistin (r=-0.157, p=0.444) and changes in visfatin (r=-
0.326, p=0.104). This is the first study looked at the relationship between protein intake 
with changes in resistin and changes in visfatin after the significant weight loss in an 
intervention group. Most of the studies in the past looked at the effect of overall dietary 
intake or fat intake on resistin and visfatin [194, 202, 203]. 
According to our results, exercise and diet-induced weight loss led to a slight 
increase in visfatin level which was statistically insignificant as compared to control 
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group which has greater increase in visfatin level. However, Cohen’s effect size value 
(d=0.68) suggested a moderate to high practical significance. This could be due to no 
change in fat free mass in both the groups during the intervention period or small sample 
size. We also found significant positive correlation of changes in resistin with changes in 
visfatin even though both resistin and visfatin tend to increase in both the groups during 
the intervention period. Diet and exercise group has slight increase as compared to 
control group which showed greater increase in both resistin and visfatin. Our study 
provided sufficient evidence to conclude that these above mentioned observations were 
due to exercise and diet-induced weight loss program and exercise training protected 
against low-grade systemic inflammation link to obesity.  
Overall, our results indicated that exercise and diet-induced weight loss affected 
anthropometric measure, inflammatory markers such as IL-6, TNF-α suggesting an anti-
inflammatory response compared to control group. Our result was in accordance with 
other research studies done on inflammatory markers, leptin, resistin and visfatin. These 
results suggested that resistin and visfatin expression was not only associated with 
weight and fat mass and inflammatory markers like TNF-α and IL-6 but they could be 
affected by fat free mass and other inflammatory markers or cytokines associated with 
obesity since the weight and fat mass loss did not result in significant reduction in 
resistin and visfatin. 
There are several limitations in conducting an exercise and diet-induced weight 
loss clinical trials that should be taken into account when interpreting the results of this 
investigation. First, the participants who volunteered to participate in our exercise and 
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diet-induced weight loss trails were often more motivated to adhere to weight loss 
programs than the general population or control group. Second, the study participants 
were continually monitored and encouraged to meet program requirements. Third, the 
results observed in our trial were limited to the population studied, sedentary and 
overweight/obese women, and might not be applicable to other populations. Although 
our finding on the effects of exercise and diet-induced weight loss on resistin and 
visfatin were novel, they should be considered preliminary as this was the first study to 
investigate the effects of exercise and diet-induced weight loss on resistin and visfatin 
and their correlation with anthropometric markers, blood markers like insulin, glucose 
and triglyceride and other inflammatory markers using blood samples collected from 
sedentary obese women compared to a control only group. Finally, study was limited 
due to small sample size. Additional research needs to be done with larger sample size to 
further assess the relationship.  
Conclusion 
 
In our investigation, participants adhering to an exercise and diet intervention 
designed to promote fat loss experienced clinically significant weight loss, 
improvements in cardiovascular endurance, positive changes in some markers of health 
and fitness. We also observed a slight increase in resistin and visfatin in diet and 
exercise group as compared to control group which had greater increase. We also 
showed statistically significant positive correlation between changes in resistin with 
changes in visfatin and changes in IL-6. This could have important implications into the 
treatment and/or management of obesity treatment because our exercise and diet-induced 
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weight loss program significant reduced markers of inflammation related to obesity in 
previously sedentary obese women. We therefore conclude that regular exercise training 
or chronic exercise adaptation reduces inflammation. Future research should evaluate the 
effect of chronic and acute exercise training on related to inflammation in obese and 
insulin resistance individuals as well as the effects of different types of diet and exercise 
on resistin and visfatin linked to inflammation, obesity, and weight loss. 
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APPENDIX A 
 
BAYLOR UNIVERSITY 
EXERCISE & SPORT NUTRITION LABORATORY 
 
Medical History Inventory 
 
Directions.  The purpose of this questionnaire is to enable the staff of the Exercise and 
Sport Sciences Laboratory to evaluate your health and fitness status.  Please answer the 
following questions to the best of your knowledge.  All information given is 
CONFIDENTIAL as described in the Informed Consent Statement. 
  
Name:____________________________________________ Age _____Date of 
Birth_______________ 
 
Name and Address of Your 
Physician:_____________________________________________________ 
 
MEDICAL HISTORY 
 
Do you have or have you ever had any of the following conditions? (Please write the 
date when you had the condition in the blank). 
 
____ Heart murmur, clicks, or other cardiac findings? ____ Asthma/breathing 
difficulty?  
____       Frequent extra, skipped, or rapid heartbeats?  ____
 Bronchitis/Chest 
Cold? 
____ Chest Pain of Angina (with or without exertion)? ____   Cancer, Melanoma, 
or Suspected Skin Lesions? 
____ High cholesterol?     ____ Stroke or Blood 
Clots? 
____ Diagnosed high blood pressure?   ____ Emphysema/lung 
disease? 
____ Heart attack or any cardiac surgery?  ____ Epilepsy/seizures? 
____ Leg cramps (during exercise)?   ____ Rheumatic fever? 
 ____ Chronic swollen ankles?    ____ Scarlet fever? 
____ Varicose veins?     ____ Ulcers? 
____ Frequent dizziness/fainting?   ____ Pneumonia? 
____ Muscle or joint problems?    ____ Anemias? 
____ High blood sugar/diabetes?   ____ Liver or kidney disease? 
____ Thyroid Disease?     ____ Autoimmune 
disease? 
____ Low testosterone/hypogonadism?   ____ Nerve disease? 
____ Gluacoma?     ____ Psychological Disorders? 
 
 
Do you have or have you been diagnosed with any other medical condition not listed? 
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_______________________________________________________________________
_____________ 
_______________________________________________________________________
_____________ 
 
Please provide any additional comments/explanations of your current or past medical 
history.  
_______________________________________________________________________
_____________ 
_______________________________________________________________________
_____________ 
 
Please list any recent surgery (i.e., type, dates etc.).  
_______________________________________________________________________
_____________ 
_______________________________________________________________________
_____________ 
 
List all prescribed/non-prescription medications and nutritional supplements you have 
taken in the last 3 months.  
_______________________________________________________________________
_____________ 
 
What was the date of your last complete medical exam?   
_______________________________________________________________________
_____________ 
 
Do you know of any medical problem that might make it dangerous or unwise for you to 
participate in this study? 
(including strength and maximal exercise tests)  ____ If yes, please explain: 
______________________________ 
_______________________________________________________________________
____________________ 
 
 
Recommendation for Participation 
 
____ No exclusion criteria presented. Subject is cleared to participate in the study. 
____ Exclusion criteria is/are present. Subject is not cleared to participate in the study. 
 
Signed: ___________________________________ Date: _____________________
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Baylor University 
Exercise & Sport Nutrition Laboratory 
 
 
Personal Information 
 
Name:                                                                                                                                                  
 
Address:                                                                                                                                                   
 
City:                                        State:                Zip Code              SS# 
______________________ 
 
Home Phone:     (      )                      Work Phone: (      )                                
 
Beeper:  (      )                             Cellular (      )                            
  
 
Fax:  (      )                             email address: ___________________ 
 
Birth date:            /            /              Age:                  Height:                Weight:                 
 
 
Exercise History/Activity Questionnaire 
 
1. Describe your typical occupational activities. 
 
 
2. Describe your typical recreational activities 
 
 
3. Describe any exercise training that you routinely participate.  
 
 
4. How many days per week do you exercise/participate in these activities? 
 
 
5. How many hours per week do you train? 
 
 
6. How long (years/months) have you been consistently training?      
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Baylor University 
Exercise & Sport Nutrition Laboratory 
 
 
Radiation Exposure Questionnaire for Women of Child Bearing Age 
 
Radiation exposure may affect fetal development.  Although the DEXA test will only 
expose you to a small amount of radiation (1.5mR per scan), you should be aware that 
there is a possibility that if you become pregnant during the course of the study that the 
x-ray exposure may be harmful to the fetus. Therefore, it is important to conduct x-ray 
tests within 10-14 days of the start of a female’s menstrual cycle if the she is of child 
bearing age, sexually active, and/or is not taking birth control pills.  The following 
questionnaire must be completed so that we know when it is an appropriate time to 
conduct the DEXA body composition tests.  Please be assured that this information will 
be kept confidential within the limits permitted by law. 
 
Current Age?      _______            
Age of first period?     _______           
Date of last period?     _______             
Normal length of menstrual cycle?   _______ 
Have you been sexually active within the last month? _______ 
Do you use birth control pills?   _______ 
Are you pregnant or have a desire for pregnancy? _______ 
 
Note:  If you happen to get pregnant during the course of this study, you must notify 
research assistants so that appropriate precautions can be made.     
 
I confirm that I have completed this questionnaire honestly and agree to notify 
researchers within the ESNL of any change in the length of my menstrual cycle and/or 
pregnancy status. 
 
___________________________________________ 
 _________________________ 
Name       Date 
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Baylor University 
Exercise & Sport Nutrition Laboratory 
 
 
NAME __________________________________ Date 
__________________________________ 
 
INSTRUCTIONS 
 
1. Record everything you eat for 4 days (including one weekend day).  If you eat 
pretzels, record how many.  If you eat a bag of chips, record the number of ounces.  
For drinks, record the number of cups or ounces. Record everything you drink 
except water. 
2. Record the Food, Amount, Brand Name, and Preparation Methods. For example:  
baked vs. fried chicken; 1 cup of rice; 2 teaspoons of margarine; 1 cup of 2% milk; 
McDonald’s, Healthy Choice, or Frosted Flakes.   
3. Record immediately after eating.  Waiting until that night may make it difficult to 
remember all foods and quantities. 
 
Food (include brand)  Method of Preparation  Quantity (cups, oz., 
no.)  
 
BREAKFAST: 
                                                                                         
 _________________________                                                                                 
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
 
LUNCH: 
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________     
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 _________________________                                             
                                                                                         
 _________________________                                             
 
DINNER: 
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
                                                                                         
 _________________________                                             
 
SNACKS: 
                                                                                        
 _________________________                                             
                                                                                        
 _________________________                                             
                                                                                        
 _________________________                                             
                                                                                        
 _________________________                                             
                                                                                        
 _________________________                                             
                                                                                        
 _________________________             
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Name __________________                       Baylor University 
Date ___________________   Exercise & Sport Nutrition Laboratory 
 
PSYCHOLOGICAL SELF REPORT INVENTORY 
 
Instructions 
 
The following items contain a series of statements that involve how people might think, 
feel, or behave.  You will be asked to indicate the extent to which each statement 
pertains to you personally.   But first, using a #2 pencil, we ask that you provide some 
important information on the left side of the computerized answer sheet (Please do not 
make any marks on the actual questionnaires themselves). 
 
This information will ONLY be used to cross-validate the questionnaire.  It will not be 
used to identify you or your answers.  In the section labeled NAME, mark your last 
name and fist name and mark your group assignment (i.e., A, B, or C) in column 10.  In 
the section labeled IDENTIFICATION NUMBER, mark the test session and fill in the 
circle (i.e., test session 2 = 2).  
 
Your answers to the items in the questionnaire are for verifying the make-up of the 
questionnaire and for research purposes.  In order to complete the questionnaire you 
should read each statement carefully and decide how you feel about it as it pertains to 
you personally.  Using a scale like the one below, indicate on the computerized answer 
sheet how much you agree or disagree with each statement by blackening the appropriate 
circle to the right of the number of the statement.  Note: Several scales are printed at the 
top of each section for easy reference since parts of the questionnaire require different 
reference points.  Please work quickly through the questionnaire and do not ponder too 
long through the assessment.  Finally, be frank and honest with your answers. 
 
Part I 
 
Below is a list of words that describe feelings people have.  Please read each one 
carefully, then circle the appropriate letter to the right which best describes HOW YOU 
HAVE BEEN FEELING DURING THE PAST WEEK AND TODAY. 
 
                                          A   B      C             D 
       E  
                                    Not At All          A Little            Moderately   Quite A Bit
  Extremely 
 
1. Friendly 
2. Tense 
3. Angry 
4. Worn Out 
5. Unhappy 
6. Clear-headed 
7. Lively 
8. Confused 
9. Sorry for things 
done  
10. Shaky 
11. Listless
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12. Peeved 
13. Considerate 
14. Sad 
15. Active 
16. On edge 
17. Grouchy 
18. Blue 
19. Energetic 
20. Panicky 
21. Hopeless 
22. Relaxed 
23. Unworthy 
24. Spiteful 
25. Sympathetic 
26. Uneasy 
27. Restless 
28. Unable to 
Concentrate  
29.  Fatigued 
30. Helpful 
31. Annoyed 
32. Discouraged 
33. Resentful 
34. Nervous 
35. Lonely 
36. Miserable 
37. Muddled 
38. Cheerful 
39. Bitter 
40. Exhausted 
41. Anxious 
42. Ready to fight 
43. Good natured 
44. Gloomy 
45. Desperate  
46. Sluggish 
   
47. Rebellious   
48. Helpless 
   
49. Weary    
50.  Bewildered 
51. Alert 
52. Deceived 
53. Furious 
54. Efficient 
55. Trusting 
56. Full of Pep 
57. Bad-Tempered 
58. Worthless 
59. Forgetful 
60. Carefree 
61. Terrified 
62. Guilty 
63. Vigorous 
64. Uncertain about 
things 
65. Bushed 
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Part II 
 
Now for a change of pace, please respond to the following statements.  Read each of the 
statements and fill in the corresponding circle on your answer sheet that best describes 
your feelings right now.  Be sure to blacken one letter choice for each group.  If more 
than one statement applies, blacken the higher letter of the alphabet.  (Example: d is 
higher than a).  
 
66. a. I do not feel sad. 
 b. I feel sad. 
 c. I am sad all the time, and I can't snap out of it. 
 d. I am so sad or unhappy that I can't stand it. 
 
67. a. I am not particularly discouraged about the future. 
 b. I feel discouraged about the future. 
 c. I feel I have nothing to look forward to. 
 d. I feel that the future is hopeless and that things cannot improve. 
 
68. a. I do not feel like a failure. 
 b. I feel I have failed more than the average person. 
 c. As I look back on my life, all I can see is a lot of failures. 
 d. I feel I am a complete failure as a person. 
 
69. a. I get as much satisfaction out of things as I used to. 
 b. I don't enjoy things the way I used to. 
 c. I don't get real satisfaction out of anything anymore. 
 d. I am dissatisfied or bored with everything. 
 
70. a. I don't feel particularly guilty. 
 b. I feel guilty a good part of the time. 
 c. I feel quite guilty most of the time. 
 d. I feel guilty all of the time. 
 
71. a. I don't feel I am being punished. 
 b. I feel I may be punished. 
 c. I expect to be punished. 
 d. I feel I am being punished. 
 
72. a. I don't feel disappointed in myself. 
 b. I am disappointed in myself. 
 c. I am disgusted with myself. 
 d. I hate myself. 
 
73. a. I don't feel I am any worse than anybody else.
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 b. I am critical of myself for my weaknesses or mistakes. 
 c. I blame myself all the time for my faults. 
 d. I blame myself for everything bad that happens. 
 
74. a. I don't have any thoughts of killing myself. 
 b. I have thoughts of killing myself, but I would not carry them out. 
 c. I would like to kill myself. 
 d. I would kill myself if I had the chance. 
 
75. a. I don't cry any more than usual. 
 b. I cry more now than I used to. 
 c. I cry all the time now. 
 d. I used to be able to cry, but now I can't cry even though I want to.
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76. a. I am no more irritated by things than I ever was. 
 b. I am slightly more irritated now than usual. 
 c. I am quite annoyed or irritated a good deal of the time. 
 d. I feel irritated all the time now. 
 
77. a. I have not lost interest in other people. 
 b. I am less interested in other people than I used to be. 
 c. I have lost most of my interest in other people. 
 d. I have lost all of my interest in other people. 
 
78. a. I make decisions about as well as I ever could. 
 b. I put off making decisions more than I used to. 
 c. I have greater difficulty in making decisions than before. 
 d. I can't make decisions at all anymore. 
 
79. a. I don't feel that I look any worse than I used to. 
 b. I am worried that I am looking old or unattractive. 
 c. I feel that there are permanent changes in my appearance that make me 
look unattractive. 
 d. I believe that I look ugly. 
 
80. a. I can work about as well as before. 
 b. It takes an extra effort to get started at doing something. 
 c. I have to push myself very hard to do anything. 
 d. I can't do any work at all. 
 
81. a. I can sleep as well as usual. 
 b. I don't sleep as well as I used to. 
 c. I wake up one to two hours earlier than usual and find it hard to get back 
to sleep. 
 d. I wake up several hours earlier than I used to and cannot get back to 
sleep. 
 
82. a. I don't get more tired than usual. 
 b. I get tired more easily than I used to. 
 c. I get tired from doing almost anything. 
 d. I am too tired to do anything. 
 
83. a. My appetite is no worse than usual. 
 b. my appetite is not as good as it used to be. 
 c. my appetite is much worse now. 
 d. I have no appetite at all anymore. 
 
84. a. I haven't lost much weight, if any, lately.
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 b. I have lost more than five pounds. 
 c. I have lost more than ten pounds. 
 d. I have lost more than fifteen pounds. 
 
85. a. I am no more worried about my health than usual. 
 b. I am worried about physical problems such as aches and pains, or upset 
stomach, or constipation. 
 c. I am very worried about physical problems, and it's hard to think of much 
else. 
 d. I am so worried about my physical problems that I cannot think about 
anything else. 
 
86. a. I have not notices any recent change in my interest in sex. 
 b. I am less interested in sex than I used to be. 
 c. I am much less interested in sex now. 
 d. I have lost interest in sex completely.
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Part III 
 
Directions:  Read each statement carefully.  For each statement, fill in the circle with the 
letter which fits you best. 
 
                  A                              B   C  D      E    
  
                   Rarely or Occasionally         Often True       Usually True      True Most 
of           Never True        
                             True               the Time   
  
 
87. I don't seem to be able to get much done at school. 
88. I dread going to school lately. 
89. I am bored with my work.  
90. I find myself getting behind in my work lately. 
91. I have accidents on the job as of late. 
92. The quality of my school work is good. 
93. Recently, I have been absent from work. 
94. I find my school work interesting and/or exciting. 
95. I can concentrate on the things I need to at school. 
96. I make errors or mistakes in my work. 
97. Lately, I am easily irritated. 
98. Lately, I have been depressed. 
99. Lately, I have been feeling anxious. 
100. I have been happy lately. 
101. So many thoughts run through my head at night that I have trouble falling asleep. 
102. Lately, I respond badly in situations that normally wouldn't bother me. 
103. I find myself complaining about little things. 
104. Lately, I have been worrying. 
105. I have a good sense of humor. 
106. Things are going about as they should. 
107. I wish I had more time to spend with close friends. 
108. I quarrel with my spouse/girlfriend/boyfriend. 
109. I quarrel with friends. 
110. My spouse/girlfriend/boyfriend and I are happy together. 
111. Lately, I do things by myself instead of with other people. 
112. I quarrel with members of my family. 
113. Lately, my relationships with people are good. 
114. I find that I need time to myself to work out my problems. 
115. I wish I had more time to spend by myself. 
116. I have been withdrawing from people lately. 
117. I have unplanned weight gains. 
118. My eating habits are erratic.
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119. I find myself drinking a lot lately. 
120. Lately, I have been tired. 
121. I have been feeling tense. 
122. I have trouble falling and staying asleep. 
123. I have aches and pains I cannot explain. 
124. I eat the wrong foods. 
125. I feel apathetic. 
126. I feel lethargic. 
 
THAT'S IT!! 
 
Thank you for your time and effort in completing this form.  If you had any questions 
concerning any questions on this assessment, please ask one of the assistants. 
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 Baylor University 
Exercise & Sport Nutrition Laboratory 
 
NAME __________________________________ Date 
__________________________________ 
 
INSTRUCTIONS 
 
Circle the number or dot between numbers that best indicates the degree you have felt 
the following symptoms during the last week: 
 
Appetite 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Hunger 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Satisfaction from Food 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Feeling of Fullness 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Amount of Energy 
 
None                              Low                            Moderate                          High                           
Severe
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0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Overall Quality of Diet 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10
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Texas A&M University 
Exercise & Sport Nutrition Laboratory 
 
Post Study Questionnaire 
 
NAME __________________________________ Date 
__________________________________ 
 
INSTRUCTIONS 
 
Circle the number or dot between numbers that best indicates the degree you have felt 
the following symptoms during the last week: 
 
Overall Impressions of the Curves 30-Minute Fitness Program 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Overall Impressions of the Weight Loss Program 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate the Difficulty in Adhering to the Fitness Program 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate the Difficulty in Adhering to the Diet 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate Your Satisfaction with the Improvements in Fitness that You Made
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None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
Rate the Satisfaction in the Changes in Body Composition that You Made 
 
None                              Low                            Moderate                          High                           
Severe 
0 . . . . . . . . . 1 . . . . . . . . . 2 . . . . . . . . . 3. . . . . . . . .4. . . . . . . . .5. . . . . . . . .6. . . . . . . . .7. 
. . . . . . . .8. . . . . . . . .9. . . . . . . . .10 
 
 
Comments/Suggestions About the Curves Fitness & Weight Loss Program
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Want to Get in Shape 
and Lose Weight? 
 
 
Women Needed for a 
Fitness & Weight Loss Study 
 
 
Researchers in the Exercise & Sport Nutrition Lab at Baylor University 
are recruiting 200 healthy, untrained, and moderately overweight female 
subjects between the ages of 18 and 50 to participate in a study to 
evaluate the effects of the Curves for Women® Fitness and Weight Loss 
Program Subjects will be required to follow an exercise program, one of 
several types of diets, and participate in five testing sessions during a 14-
week period.   Eligible subjects will receive free supervised training, body 
composition/bone density screening, exercise tests, nutritional 
counseling, and $125 for completing the study. 
 
 
For more information call: 
 
Exercise & Sport Nutrition Lab 
Department of HHPR 
MCL 122 
254/710-7199
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Weekly Follow-up Assessment 
 
Effects of Calcium Supplementation on Body Composition, Metabolism, and Exercise Capacity in Post-Menopausal  
Women participating in the Curves for Women® Fitness and Weight Loss Program 
 
Subject Name:  ____________________  Subject #:  _____  Date:  __________ 
 
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Are you training on 
schedule? 
              
Are you following the 
diet plan? 
              
Rate the frequency of the 
following symptoms 
according to the scale 
where: 
0 = none 
1 = minimal (1-2 per/wk) 
2 = slight (3-4 per/wk) 
3 = occasional (5-6 
per/wk) 
4 = frequent (7-8 per/wk)  
5 = severe (9 or more 
per/wk) 
              
Dizziness?               
Headache?               
Fast or racing heart rate?               
Heart skipping or 
palpitations? 
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Shortness of breath?               
Nervousness?               
Blurred Vision?               
Any other unusual or 
adverse effects? 
              
Rate the severity of the 
following symptoms 
according to the scale 
where: 
0 = none 
1 = minimal  
2 = slight 
3 = moderate 
4 = severe  
5 = very severe  
              
Dizziness?               
Headache?               
Fast or racing heart rate?               
Heart skipping or 
palpitations? 
              
Shortness of breath?               
Nervousness?               
Blurred Vision?               
Any other unusual or 
adverse effects?  
              
Nurse signature:   
Melyn Galbreath MSN, 
FNP-C 
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PLEASE REMEMBER TO COMPLETE THIS QUESTIONNAIRE WEEKLY AT THE SLC 
Further Questions: Contact the Research Nurse, Melyn Galbreath at 710-7199/3243 or by e-mail @ 
May_Galbreath@baylor.edu 
Thank you for your participation! 
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APPENDIX B 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial:  The effects of the Curves 90-Day Fitness Challenge on health outcomes in 
women.     
Demographics  ESNL Staff 
Initials:  _____ 
Name: _________________________ Testing Session:  _____
Group:  _____  
Date:  _____      D.O.B.:  _____ Age:  
_____ 
Resting Measures ESNL 
Staff Initials:  _____ 
Psychological Questionnaires/Informed Consent: 
HLKN Informed consent:  _____ Body Image:  _____ 
Radiation consent:  _____ MOS SF-36:  _____  
Activity Log:  _____  Eating Satisfaction:  _____ 
Food Log:  _____ Post-Study Questionnaire (T4 only):  
_____  
Physiological Parameters:   ESNL Staff 
Initials:  _____ 
Height:  _____ in.  Waist: _____in. 
Weight:  _____ lb.  Hip: 
_____in.  
REE #1:  _____   Resting H.R.:  _____bpm.  
Time:   _____am Resting B.P.:  _____/_____mmHg 
Last Meal:   _____am/pm  BIA: _____ 
Hrs Fasted: _____hr.  Handheld BIA:  _____ 
#1 or #2 
Last Wkout: _____  DEXA #2:  _____ 
Lab (EBNL): _____ (2) SST Tubes/ (1) EDTA Tube ECG (Rest): 
_____ #1 or #2 
Time: _____am Max Test:    _____ 
#1 or #2 
Yr. /Menopause _______ Notes:  
_____ 
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Exercise Measures:  Strength Testing:  ESNL Staff 
Initials:  ____ 
Leg Press:  Foot Position:  _____  Sled Position:  _____  
Preceding Weights/Reps:   
_____x_____: _____x_____: _____x_____: _____x_____: _____x_____: 
_____x_____: ____x_____ 
1 RM:  _____ 
80% 1RM:  _____ 80% 1RM repetitions:  _____ 
Bench Press:  Hand Position:  _____  
Preceding Weights/Reps:   
_____x_____: _____x_____: _____x_____: _____x_____: _____x_____: 
_____x_____: _____x_____ 
1 RM:  _____ 
80% 1RM:  _____ 80% 1RM repetitions:  _____ 
Updated 10/01/2010 
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CONSENT FORM 
The effects of the Curves 90-Day Fitness Challenge on health outcomes in women 
Introduction 
The purpose of this form is to provide you information that may affect your decision as to whether 
or not to participate in this research study. If you decide to participate in this study, this form will 
also be used to record your consent. 
You have been asked to participate in a research project comparing the Curves International fitness 
and weight loss program to other popular weight loss programs. The purpose of this study is to 
determine the effects of the new Curves 90-Day Fitness Challenge on health outcomes in women. 
You were selected to be a possible participant because you met all entrance criteria for this study. 
This study is being sponsored/funded by Curves International. 
What will I be asked to do? 
If you agree to participate in this study, you will first be asked to sign an Informed Consent 
statement in compliance with the Human Subject’s Protection Program (HSPP) at Texas A&M 
University and the American College of Sports Medicine. You will then be familiarized to the 
study requirements, food log recording and tests to be conducted during the study. This session 
will take approximately one hour to complete. Prior to reporting to the lab for baseline testing, you 
will record all food that you eat on dietary record forms for four days (including one weekend 
day). You will not exercise for 48 hours nor eat for 12 hours prior to reporting to the lab for baseline 
testing. You will then undergo a battery of tests as described in Table 1. You will fill out a 
Demographic Form, a Health History Form, A Radiation Safety Form, a Quality of Life 
Questionnaire, a Body Image Questionnaire and an eating Satisfaction Questionnaire. You will 
also be required to report any adverse side effects that you may experience on a weekly basis.  
You will then continue with the tests as described in Table 1. You will first be weighed and have 
your resting energy expenditure (REE) determined. This will involve lying down on an exam table 
and having a light blanket placed over you to keep you warm and placing ear plugs in your ears to 
reduce distractions. A see through plastic canopy will then be placed over your neck and head so 
that the air that you breathe can be measured for oxygen and carbon dioxide. You should stay 
motionless without going to sleep for 15-minutes so that your resting energy expenditure can be 
calculated. You will then donate about 20 milliliters (4 teaspoons) of venous blood from a vein in 
your arm. Blood samples will be obtained by standard/sterile procedures using a needle inserted 
into a vein in your arm. Personnel who will be taking your blood are experienced in phlebotomy 
(procedures to take blood samples) and are qualified to do so under guidelines established by the 
Texas Department of Health and Human Services. This will take about 5-minutes. You will then 
have your total body water determined using a bioelectrical impedance analyzer (BIA). The BIA 
analysis will involve lying down on your back on a table and having two small electrodes placed 
on your right hand and your right foot. The analyzer wires will be attached and a small and safe 
current (500 microamps at a frequency of 5- kHz) will pass through your body so that the amount 
of water can be measured. This analyzer is commercially available and has been used in the health
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care/fitness industry as a means to assess body composition and body water for over 20 years. The 
use of this device has been approved by the Food and Drug Administration (FDA) to assess total 
body water and the current to be used has been deemed safe. Your body composition and bone 
density will then be determined by using a Discovery W dual energy x-ray absorptiometer 
(DEXA). This will involve lying down on your back on the DEXA exam table in a pair of shorts 
or a gown for about 6 minutes. A low dose of radiation will scan your entire body to determine the 
amount of fat weight, muscle weight, and bone weight. You will be exposed to an x-ray dose that 
is similar to the amount of natural background radiation a person would receive in one month while 
living in College Station. After this test, you will have resting blood pressure determined using a 
blood pressure cuff and stethoscope and heart rate determined by taking your pulse. You will then 
be prepared to perform a maximal treadmill test. You will have your right and left shoulder, right 
and left part of your stomach, and several places around your upper chest and below your bra line 
rubbed with alcohol gauze. Ten (10) electrocardiograph (ECG) electrodes will then be placed on 
your shoulders, chest, and stomach and you will be attached to an ECG to evaluate your heart. You 
will then be positioned on the treadmill and a sterile mouthpiece will be placed in your mouth and 
a mouthpiece holder will be placed on your head. A nose clip will be placed on your nose and that 
the air you breathe will be measured for oxygen and carbon dioxide content. Once the equipment 
is attached, you will be given instructions to begin walking on the treadmill. You will then perform 
an exercise test that involves increasing the speed and grade you are walking on the treadmill until 
you reach your maximal effort. Heart rate, ECG tracings, blood pressure and your ratings of 
exertion will be monitored throughout the test. Once you reach your maximum, you will undergo 
a slow walking and seated recovery period. This test will take about 30 minutes to complete. You 
will then perform a one repetition maximum (1RM) and 80% of 1RM endurance repetition test on 
the bench press and hip/leg sled using standard procedures. This will involve warming up and 
performing successive one repetition lifts on the bench press until you determine your 1 RM. You 
will then rest for 5-minutes and lift 80% of your 1 RM as many times as you can. You will then 
rest for 10-minutes and follow the same procedure in determining your 1 RM and 80% of 1 RM 
on the hip/leg sled. These tests will take about 20 minutes to complete. The same battery of tests 
will be performed at the post-study assessment 16 weeks into the study protocol. All the 
assessments minus the exercise tests will also be performed at 4, 6 10 and 12 weeks into the study 
protocol. Each testing session will take between 1.5 and 3 hours to complete. In the event of an 
emergency during an exercise test proper emergency response protocols (calling 9-911 for serious 
injury or a medical emergency, calling Biosafety/EHS for cleanup assistance or spill team 
response, calling UPD for incidents in public areas, retrieving AED located in the lab, performing 
CPR or other First Aid techniques, etc.) will be followed by the Exercise & Sport Nutrition 
Laboratory (ESNL) Staff depending on the severity of the emergency.  
After baseline testing, you will be matched based on age, BMI, activity level and eating habits and 
randomized into one of six intervention groups as described in Table 2. The Operating Systems 
(OS) Questionnaire (or Initial Assessment) will be used to help determine the group assignments. 
This will include a high protein/low fat diet group (30% CHO, 45% PRO, 25% FAT, N=60), a 
high carbohydrate/low fat diet group (45% CHO, 30% PRO, 25% FAT, N=60), a Weight Watchers 
diet group (N=60), a Jenny Craig diet group (N=60), a Nutrisystem diet group (N=60) and a control 
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group (N=60). In addition one additional group will follow the high protein/low fat diet group 
(30% CHO, 45% PRO, 25% FAT, N=60) and record diet and activity progress on-line.  
If you are randomized into one of the first two groups (N=120), or the additional one group that 
will utilize the on-line recording system (N=60), you will diet for 7 days at 1,200 kcals/day and 
then 1,500 kcals/day for the remaining 11 weeks of the study. If you are in one of the first two 
groups, or the additional one group that will utilize the on-line recording system, you will meet 
weekly one on one with your weight loss coach for the duration of the study for weekly weigh-ins. 
Each meeting will take place in the ESNL and will last approximately 15 minutes. The coach will 
guide you through each phase of the program, assist with meal planning, assist with goal setting 
and provide accountability and encouragement in order to meet your fitness and nutrition goals. If 
you are randomized into the third group (N=60) you will follow the Weight Watchers Momentum 
Program that is based on their four pillar approach (food, exercise, behavior and support). Every 
food has a POINTS value, based on its calories, fat and fiber. The Momentum program uses 
POINTS values to help keep track of what you eat. A POINTS “budget” will be personalized for 
you at the weekly meetings. You will be required to attend at least one meeting per week at the 
local Weight Watchers facility located at 4001 E. 29th Street, Suite 112 in the Carter Creek Center 
in Bryan, Texas. Membership dues/passes to the Weight Watchers program/facility will be covered 
for you during the duration of the study. If you are randomized into groups four or five (N=120 
total), you will follow the dietary guidelines set forth by those respective plans. The sixth group 
(N=60) will act as a control group. If you are randomized into this group you will not follow a 
prescribed nutrition program but will continue with your normal daily habits. Everyone, regardless 
of group assignment, will keep a food record and food frequency log to monitor dietary 
compliance. If you are randomized to participate in the first two groups (N=120 total), or the 
additional one group that will utilize the on-line recording system (N=60), you will participate in 
the Curves 30-minute fitness program three times per week throughout the investigation. The 
Curves program involves performing thirteen hydraulic resistance exercise machines that utilize 
bidirectional resistance that work all major muscle groups. These are interspersed with floor-based 
calisthenics exercises designed to maintain an elevated heart rate. Research has shown that 
exercise intensity averages 65% of maximal aerobic capacity and that participants generally 
perform 50 – 75% of 1 repetition maximum on the main exercise machines. The new Curves 
equipment includes the attached force measurement and feedback system. You will be instructed 
to push hard enough to generate a green light on the feedback panel for each repetition. You will 
be instructed to wear heart rate monitors (HR) to access exercise intensity. All exercise sessions 
will be held in the ESNL. Research Assistants will monitor your exercise sessions and record your 
attendance. You will also be encouraged to walk for 30-minutes at a brisk pace (60 – 80% of heart 
rate reserve) on days you do use the Curves equipment. If you are randomized to participate in 
third group (N=60) you will start by focusing on the food plan and then incorporate the specifics 
of activity a week alter once you have had the chance to get comfortable with the eating plan. After 
a week of reducing sedentary behavior, the POINTS Activity System is introduced. In a way that 
complements the POINTS values of food, a formula that calculates the POINTS values for activity 
is used. The formula is based on body weight, the amount of time the activity is done, and the level 
of intensity. This method enables you to do any exercise or activity that is enjoyable and fits within 
your lifestyle. If you are assigned to groups four, five or six (N=120 total) you will not follow a 
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prescribed exercise program but will continue your normal daily habits. Everyone, regardless of 
group assignment, will be required to complete activity logs to monitor exercise frequency and 
intensity.  
Please do your best to: 1) follow the instructions outline by the investigators; 2) show up to all 
scheduled testing and training sessions; and 3) follow the diet prescribed and do not take any other 
nutritional supplements or performance enhancing aids during this study (i.e., vitamins/minerals, 
creatine, HMB, androstenedione, DHEA, etc). In addition, please do not take any non-medically 
prescribed medications and report any medication that is prescribed for you to take during this 
study. If you take any other nutritional supplements or medications during the course of the study 
that may affect vitamin/mineral status, body composition, or strength you may be removed from 
the study. 
What are the risks involved in this study? 
The risks associated with this study are: You will be exposed to a low level of radiation during the 
DEXA body composition tests, which is similar to the amount of natural background radiation you 
would receive in one month while living in College Station. In addition, a very low level of 
electrical current will be passed through your body using a bioelectrical impedance analyzer (BIA). 
This analyzer is commercially available and has been used in the health care/fitness industry as a 
means to assess body composition and body water for over 20 years. The use of the BIA and 
DEXA analyzers have been shown to be safe methods of assessing body composition and total 
body water and are approved by the FDA. You will donate about 4 teaspoons (20 milliliters) of 
venous blood four (4) times during the study using standard phlebotomy procedures. This 
procedure may cause a small amount of pain when the needle is inserted into the vein as well as 
some bleeding and bruising. You may also experience some dizziness, nausea, and/or faint if you 
are unaccustomed to having blood drawn. The exercise tests that will be performed may cause 
symptoms of fatigue, shortness of breath, and/or muscular fatigue/discomfort. The exercise tests 
may also cause short-term muscle soreness and moderate fatigue for several days following the 
tests. You may also experience muscle strains/pulls during the exercise testing and/or training 
program. However, exercise sessions will be conducted by trained personnel and monitored to 
ensure you follow appropriate exercise guidelines. You will follow a prescribed dietary regimen 
involving consuming 1,200 or 1,500 calories per day during various phases of the program. In 
addition, one group will ingest a high percentage of calories in the form of protein. Although the 
total amount of total protein is not excessive (100-220 grams/day or 1.1 - 2.3 grams/kg/day for a 
95 kg female) it may be higher than you are accustomed to ingesting and may exceed 
recommended protein intake for active individuals (i.e., 1-2 grams/kg/day). As a result, you may 
experience weight loss or gain, feelings of hunger or fullness, and/or changes in appetite and/or 
mood during various phases of the dietary intervention. The likelihood of any of these occurring 
is slim. 
146 
What are the possible benefits of this study? 
The possible benefit you may receive from participation in this study is increased physical fitness 
and improvements in body composition. You may also gain insight about your health and fitness 
status from the assessments that will be performed. 
Do I have to participate? 
No. Your participation is voluntary. You may decide not to participate or to withdraw at any time 
without your current or future relations with Texas A&M University being affected. 
Will I be compensated? 
You will receive $125 (i.e., $25 for each familiarization and experimental session) upon 
completion of the study. Disbursement will occur upon completion of all sessions and after all 
study related materials (food logs, training logs, etc.) are turned in. In the event you withdraw from 
the study prior to completion disbursement will occur on a pro-rated basis. 
Who will know about my participation in this research study? 
The records of this study will be kept private. No identifiers linking you to this study will be 
included in any sort of report that might be published. Research records will be stored securely 
and only Mr. Christopher Rasmussen and Dr. Richard Kreider will have access to the records. 
Whom do I contact with questions about the research? 
If you have questions regarding this study, you may contact Dr. Richard Kreider, 945-1333, 
rkreider@hlkn.tamu.edu or Mr. Christopher Rasmussen, 458-1741, crasmussen@hlkn.tamu.edu. 
Whom do I contact about my rights as a research participant? 
This research study has been reviewed by the Human Subjects’ Protection Program and/or the 
Institutional Review Board at Texas A&M University. For research-related problems or questions 
regarding your rights as a research participant, you can contact these offices at (979)458-4067 or 
irb@tamu.edu. 
Signature 
Please be sure you have read the above information, asked questions and received answers to your 
satisfaction. You will be given a copy of the consent form for your records. By signing this 
document, you consent to participate in this study. 
Signature of Participant: _____________________________________Date: ______________ 
Printed Name: ________________________________________________________________ 
Signature of Person Obtaining Consent: _________________________Date: ______________ 
Printed Name: ________________________________________________________________ 
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